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PREFACE
May the fundamental goal of this project be achieved, for women at-risk for hereditary breast
cancer to justly and promptly gain this knowledge, in order to guide preventive health care
actions that promote optimal quality and quantity of life.

“Health, the greatest of all we count as blessings.” – Ariphron

“Think left and think right and think low and think high. Oh, the thinks you can think up if only
you try!”

– Dr. Seuss
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ABSTRACT
Breast cancer is the foremost new cancer diagnosis and the second highest cause of cancer
death in American women (American Cancer Society, 2019). Hereditary breast cancer is most
commonly caused by a mutation within the breast cancer susceptibility genes, BRCA 1 or 2,
which increases women’s risk for breast cancer by five to ten-fold the average population (Mayo
Clinic, 2019). The U.S. Preventive Services Task Force has assigned a Grade B
recommendation advising health care providers to use a risk assessment tool, such as the
Breast Cancer Genetics Referral Screening Tool (B-RST™), to recognize and provide medical
management recommendations for high-risk women (Nelson, Pappas, Cantor, Haney, &
Holmes, 2019). Offering medical management options to this at-risk group can promote breast
cancer prevention or early detection to positively affect health outcomes (ACOG, 2019; Kiely &
Schwartz, 2014). The purpose of this evidence based practice (EBP) project was to determine
if using the B-RST™ would aid in identifying women who are candidates for cancer genetic
and/or High Risk Breast Clinic (HRBC) counseling, in comparison to the approach of reviewing
cancer family history in the electronic medical record (EMR). The seven steps of the Iowa
Model (Iowa Model Collaborative, 2017) guided this EBP protocol implementation. During a 12week time period 994 women seen at a nine provider obstetrical and gynecological practice in a
Midwestern state had a B-RST™ assessment performed during routine gynecological and new
patient appointments. Data were collected by completing and recording the B-RST™ results in
the EMR, reviewing populated reports, and performing chart audits. Additionally, chart audits
established participation in scheduling and attending referral consultation appointments.
Demographic information was obtained for the pre-protocol patient group (N = 880) along with
genetics (N = 8) and HRBC (N = 6) referrals for the same 12-week time period one year prior.
During this EBP project, a total of 994 participants had the B-RST™ assessment performed.
Genetics referrals were provided to 32 (18.4%) of the 174 participants who qualified, with six
(21.9%) of the appointments completed. From the 249 participants eligible for a HRBC

x

consultation, 57 (22.9%) received referrals and eight (14.0%) participants had this performed. A
Chi-square test for independence resulted in p values > .05 for the variables of age,
appointment type, insurance, race, and religion; thus determining the sampling was
representative of the office population. Factorial ANOVA analyses were statistically significant
for the effects of the health care providers using the B-RST™ to guide both HRBC (F(6, 1860),
= 9.23, p <.001) and genetics (F(6, 1860) = 6.46, p < .001) referrals. It was determined that use
of the B-RST™ was an effective method for identifying, and subsequently providing appropriate
referrals, to women who are at-risk for hereditary breast cancer at an Ob/Gyn office setting.
Future EBP projects and research should focus on methods to: (a) educate health care
providers about hereditary breast cancer, its associated risks, and B-RST™ use to promote risk
assessment utilization, (b) increase health care provider HRBC and genetics referral rates to
provide identification and medical management for those at-risk, and (c) recognize and address
patient-reported barriers to improve referral acceptance and participation rates.
Keywords: BRCA 1 or 2, breast cancer, Breast Cancer Genetics Referral Screening
Tool, B-RST™, genetics referral, hereditary breast cancer, High Risk Breast Clinic, protocol,
referral
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CHAPTER 1
INTRODUCTION
Background
Being diagnosed with cancer is a formidable reality that many individuals face. In the
United States (U.S.), cancer is second only to cardiovascular disease for leading causes of
death (Centers for Disease Control and Prevention, 2018). In American women, breast cancer
is currently the foremost new cancer diagnosis and the second highest cause of cancer death.
In 2019, it is estimated there will be 268,600 new breast cancer cases in women in the U.S. and
that 41,760 will die from this cancer (American Cancer Society [ACS], 2019). Many factors
influence women’s risk of acquiring breast cancer. An important role of a health care provider is
assessing and identifying women who have an elevated predisposition for breast cancer, in
order to offer additional medical management options which promote breast cancer prevention
or early detection (Cusack Jr & Hughes, 2012; Kiely & Schwartz, 2014).
Risk factors for breast cancer are categorized as non-modifiable and modifiable.
Female gender and advancing age, predominantly beyond 50 years old, are two primary nonmodifiable risks (ACS, 2017a; Kiely & Schwartz, 2014; Smith, Mester, & Eng, 2014). According
to the ACS (2017a), additional non-modifiable risk factors include: (a) ethnicity; (b) race; (c)
family history of breast cancer; (d) hereditary breast cancer gene mutations; (e) fetal exposure
to diethylstilbestrol; (f) early menarche; (g) late menopause; (h) dense breast tissue; (i) specific
benign breast conditions; and (j) prior chest radiation before 40 years old. Modifiable risk
factors for the development of breast cancer include: (a) lack of physical activity; (b) being
overweight or obese; (c) consuming more than two or three units of alcohol daily; (d) being
nulliparous; (e) not breastfeeding; (f) using certain forms of contraception; (g) taking combined
hormone replacement therapy after menopause (ACS, 2017b). For the purpose of this
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evidence-based practice (EBP) practice project, the primary emphasis is the non-modifiable risk
factor of the hereditary breast cancer gene mutations BRCA1 and 2.
Thoroughly reviewing an individual’s personal and family cancer histories assists in
differentiating between hereditary, familial, and sporadic breast cancers. It is estimated that 510% of breast cancers are hereditary, 15-20% are familial, and the remainder are considered
sporadic (Meaney-Delman & Belcross, 2013). Hereditary breast cancer “red flag”
characteristics include any of the following personal and family histories: (a) breast cancer prior
to 50 years old, (b) breast and/or ovarian cancer in multiple family members in many
generations, (c) bilateral breast occurrence and/or multiple metastases spread from the same
primary site, (d) incidence of less prevalent cancers (e.g., fallopian tube, ovarian, peritoneal,
male breast), (e) one or more diagnosed gene mutations, and (f) certain populations (e.g.,
Ashkenazi Jewish) (Meaney-Delman & Bellcross, 2013). Familial breast cancers typically occur
after the age of 50 years old, are in several family members without a pattern, tend to be
unilateral, and are noted to have an association between genetics and one’s environment
(Meaney-Delman & Bellcross, 2013; Smith et al., 2014). In contrast, the majority of breast
cancer occurrence is considered sporadic with onset after 60 years old, occurs unilaterally, is
unassociated with familial rates of breast or other related cancers, and is often associated with
environmental and modifiable risk factors (Meaney-Delman & Bellcross, 2013).
In 2003, one of the most significant advancements in medicine occurred when
sequencing of the human genome was completed (National Institutes of Health [NIH], 2017).
Since then, much has been learned about the genome, or entire collection of genes, comprising
the human body (NIH, 2017). Inherited changes within a gene, classified as a mutation or a
pathogenic variant, can increase an individual’s predisposition for cancer development
depending on the specific gene and location of the modification (Buys et al., 2017; NIH, 2017).
Inheriting a gene mutation from one or both parents increases the likelihood of cancer

HEREDITARY BREAST CANCER PROTOCOL

3

occurrence and accounts for up to 10% of breast cancer diagnoses (ACS, 2017a; Senter &
Hatfield, 2016).
The most common cause of hereditary breast cancer evolves from germline mutations of
breast cancer susceptibility gene 1 (BRCA1) or breast cancer susceptibility gene 2 (BRCA2);
hereafter collectively referred to as breast cancer gene (BRCA), unless noted otherwise
(Bayraktar & Arun, 2017; Smith et al., 2014). All individuals have these two genes, which
ordinarily serve the purpose of generating proteins that inhibit tumor production (NIH, 2018). In
an individual with a BRCA mutation, cancer cells are allowed to proliferate when damaged DNA
is not corrected properly (NIH, 2018). An estimated 1/300 to 1/500 individuals have a BRCA
gene mutation (Nelson, Pappas, Cantor, Haney, & Holmes, 2019). Women of Ashkenazi
Jewish descent have an even higher predisposition of 1/40 of inheriting this gene mutation
(McReynolds, 2017). Whereas the average American woman has an estimated 12% lifetime
risk of breast cancer, women with a BRCA mutation confront a significantly increased lifetime
risk of up to 72% (McReynolds, 2017).
BRCA-related cancers characteristically affect individuals at younger ages with
increased susceptibility to additional cancer diagnoses during their lifetime (McReynolds, 2017).
Besides breast cancer, BRCA mutations are also associated with elevated risks for the following
malignancies: (a) fallopian tube; (b) ovarian; (c) pancreatic; (d) peritoneal; and (e) prostate
(Bayraktar & Arun, 2017; NIH, 2018). Melanoma is another malignancy associated specifically
with BRCA2 (Bayraktar & Arun, 2017; Hampel, Bennett, Buchanan, Pearlman, & Wiesner, 2015;
Smith et al., 2014).
Although there are additional hereditary gene mutations known to elevate breast cancer
susceptibility, the most prevalent encompass the BRCA1 and BRCA2 mutations (Couch et al.,
2017). These two mutations are associated with a five to ten-fold increase in lifetime risk for
breast cancer and represent five to ten percent of breast cancer diagnoses annually (MeaneyDelman & Bellcross, 2013; Mayo Clinic, 2019; Nair et al., 2015). Since breast cancer is the
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predominant BRCA-related malignancy risk, with medical management options available to
potentially decrease or prevent disease occurrence, the focus of this EBP project is on
appropriate and timely identification and referral of woman at risk for having this gene mutation.
Data from the Literature Supporting Need for the Project
A widespread consensus exists amidst many professional medical organizations and
societies emphasizing the importance of obtaining and assessing an individual’s personal and
family medical histories for inherited hereditary breast cancer risk in order to provide additional
medical management options. In August 2019, the U. S. Preventive Services Task Force
(USPSTF) updated their 2005 recommendation statement for BRCA-related cancer risk
assessment with an initial online publication. These guidelines inform the care for the
population of women who may be at risk of having a BRCA mutation (Nelson et al., 2019).
According to the USPSTF guidelines, further evaluation and management is suggested when
any of the following are noted in a family’s cancer history: (a) BRCA-related cancers; (b) breast
cancer prior to the age of 50; (c) numerous members with breast cancer; (d) cancer affecting
both breasts; (e) presence of both breast and ovarian cancer; (f) male breast cancer; and (g)
Ashkenazi Jewish ethnic background (Moyer, 2014).
The 2019 USPSTF update again provided a grade B recommendation for risk
assessment and encouraged use of a screening risk assessment tool for BRCA gene mutations
in women with a family history of breast and/or ovarian cancer to determine appropriate
candidates for genetic counseling referrals (Nelson et al., 2019). A grade B recommendation
indicates that health care providers should perform this service as it is determined to provide at
least a moderate benefit to an individual (USPSTF, 2017). In agreement with the prior update in
2013, this recommendation continues to support the need to “Screen women whose family
history may be associated with an increased risk for potentially harmful BRCA mutations.
Women with positive screening results should receive genetic counseling and, if indicated after
counseling, BRCA testing” (Moyer, 2014, p. 272). Although a particular risk stratification tool
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wasn’t suggested for this screening assessment, of the eight tools evaluated by the USPSTF,
the Referral Screening Tool (now called B-RST™) and the Seven-question Family History
Screening are the two that received the highest quality rating of good; the ratings are
categorized as fair, fair to good, and good (Nelson et al., 2019).
The National Comprehensive Cancer Network (NCCN) updates clinical practice
guidelines at least annually for a multitude of cancers. Version 3.2019 of Genetic/Familial High
Risk Assessment: Breast and Ovarian, contains genetic breast cancer assessment criteria that
are more specific than those delineated by the USPSTF (NCCN, 2019b). These criteria are
provided to assist with determining appropriate candidates for hereditary cancer genetic
services and are differentiated between individuals with and without a history of BRCA-related
cancers. According to the NCCN (2019b), an accurate family history assessment incorporates
all biological female and male family members, which then supports separate evaluation of
maternal and paternal lineage. NCCN guidelines are based on EBP, are frequently referenced
by professional organizations and societies, and guide medical management of individuals at
increased risk or already affected by cancer (NCCN, 2019b).
In a Committee Opinion focusing on family history originally published in 2011 and
reaffirmed in 2018, The American College of Obstetricians and Gynecologists (ACOG) asserted,
“Family history information should be reviewed and updated regularly, especially when there are
significant changes to family history. Where appropriate, further evaluation should be
considered for positive responses, with referral to genetic testing and counseling as needed”
(2018, p.1). Those considered to be at elevated susceptibility should subsequently be referred
for genetic counseling with testing if determined necessary. Utilization of a family history
assessment tool or performance of a minimum of a three-generation pedigree is proposed. If
use of a screening tool is preferred, care should be taken to ensure that it is applicable to the
population of patients within the community where the practice is located (ACOG, 2018).
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The Nurse Practitioners in Women’s Health (NPWH) emphasized that hereditary breast
cancer risk assessment needs to be part of routine care (NPWH, 2017). This risk evaluation
ideally incorporates (a) the cancer history of the individual and her first-, second-, and thirddegree maternal and paternal relatives, (b) detailing the age at diagnosis, and (c) location of the
primary cancer. In addition, it is important to determine if there is Ashkenazi Jewish heritage
and genetic test results available for any relatives (NPWH, 2017). This organization
recommended the use of screening tools to determine appropriate candidates for genetic
counseling with possible testing. In congruence with USPSTF and ACOG guidelines, specific
screening tools weren’t recommended, but having a strategy for approaching a hereditary
breast cancer risk assessment is necessary. “A system should be established within WHNPs’
[Women’s Health Nurse Practitioners’] practice settings for referral, consultation, and/or
collaboration to ensure that women have timely access to genetic counseling services and
subspecialty follow-up” (NPWH, 2017, para. 4).
The American College of Medical Genetics and Genomics and the National Society of
Genetic Counselors collaborated and released clinical guidelines for cancer assessment
referrals (Hampel et al., 2015). These organizations recognized the challenging barriers health
care providers confront with timely identification and management of individuals at elevated
propensity for developing cancer. Similar to the NCCN guidelines, criteria for genetic referrals
are based on specific risk factors that encompass personal and family history attributes (Hampel
et al., 2015).
According to Cotton and Kirkpatrick (2017), merely one of the fourteen million women in
the U.S. who qualify for BRCA testing have actually performed genetic testing. It is estimated
that amongst individuals who have a BRCA gene mutation, only 30% of breast cancer survivors
and 10% without a history of BRCA-related cancer have been identified through genetic testing
(Drohan, Roche, Cusack, and Hughes, 2012). Besides the potential health consequences, not
assessing risk factors and offering genetic services can result in medical malpractice lawsuits.
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For breast cancer lawsuits, the highest in frequency and payouts occur with women who are
younger than 50 years old, often related to an increase in cancer aggression and fatality rates
(Cotton & Kirkpatrick, 2017). To apply an understanding of potential hereditary cancer risks to
all aspects of a woman’s health care, Snow (2014) strongly encourages hereditary cancer risk
assessment performance at each office visit. Furthermore this physician asserts, “preventing
life-threatening illness, such as hereditary cancer, is the most important part of our job” (Snow,
2014, p. S4).
Data from the Clinical Agency Supporting Need for the Project
Between the years of 2011 and 2015, Lake and Porter counties in Northwest Indiana
had an average of 395 and 127 annual cases of breast cancer respectively, making them the
2nd and 7th leading counties of breast cancer prevalence in this state (State Cancer Profiles,
2015). In the state of Indiana, approximately 5,820 new cases of breast cancer in women are
predicted to occur and nearly 870 will succumb to this condition in the year 2019 alone (ACS,
2019). From June 1, 2018 to June 1, 2019, over 21,500 patient appointments occurred at an
obstetrical and gynecological (Ob/Gyn) practice with five offices locations at that time in
Northwest Indiana (H. Hendricks, personal communication, June 3, 2019). Amongst these
appointments, 3,415 were for routine gynecological examinations and 1,746 were new patients
establishing care. This practice currently employs three physicians, three nurse practitioners
(NPs), and three certified nurse midwives (CNMs). Within this practice group, collaborative
agreements exist between the advanced practice registered nurses (APRNs) and the
physicians, but each practitioner provides patient care with a relatively independent approach
(L. Williams, personal communication, June 11, 2019). This Ob/Gyn practice does not have a
protocol for the method in which patients are screened and offered referrals for genetic
counseling and testing (L. Williams, personal communication, June 11, 2019). Currently, there
is a lack of consistency for assessing, and/or documenting assessing, women’s personal and
family medical histories for hereditary breast cancer risk. Therefore, depending upon the
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provider a patient is scheduled to see in this practice group, only a portion of women who are
appropriate candidates for hereditary breast cancer risk assessment may be evaluated and
offered a referral for genetic screening services and subsequent follow-up. Development and
utilization of an EBP protocol will promote more consistent and thorough care of this at-risk
population of women.
Purpose of the Evidence-Based Practice Project
The purpose of this EBP project is to answer the following compelling clinical question:
In an obstetrical and gynecological practice, what is the best clinical practice for implementing a
protocol for identifying women at increased risk for hereditary breast cancer, in order to refer
appropriate candidates for genetic services? Additional queries consider whether the health
care providers and support staff will consistently utilize the protocol; and, in order to determine
strategies to improve protocol adherence, what are identified barriers and benefits to its use?
PICOT Question
Clinical inquiry promotes the continuous advancement of EBP. The PICOT format is
commonly utilized to guide the process of formulating the EBP question (Adams, 2015; FineoutOverholt & Stillwell, 2019). The “P” represents the specific population or problem of concern.
“I” stands for the intervention or issue that is of importance. The “C” delineates the comparison,
such as when an intervention is contrasted to a specific standard of care. “O” is for the
identified and measured outcome(s). If applicable to the topic, the “T” designates a reference of
time.
The PICOT question for this EBP project is: In women cared for in an obstetrical and
gynecological practice (P) how does utilization of a breast cancer genetics referral screening
tool (I) as compared to the current standard of care of collecting and reviewing family history in
patients’ electronic medical record (C) allow women at increased risk for hereditary breast
cancer to be appropriately identified and referred for genetic counseling (O) within a twelveweek time frame (T)?
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Significance of the EBP Project
Protocols provide structure and consistency amongst health care providers in a group
practice. ACOG promotes protocol development and utilization to facilitate complying with
standards while providing continuity of care, which has demonstrated improved patient safety
(2019). To promote successful utilization, ACOG (2019) suggests health care providers should
be “. . .engaged in the process of developing guidelines and presenting data to help foster
stakeholder buy-in and create consensus, thus improving adherence to guidelines and
protocols” (p. 1). The NPWH (2017) agree that, “An evidence-based protocol established
according to guidelines provided by nationally recognized organizations such as NCCN must be
followed to ensure that all recommended components of assessment, counseling, informed
consent, appropriate testing, and follow-up are followed” (para. 3).
With the ultimate goal of decreasing hereditary breast cancer incidence, timeliness of
BRCA gene mutation identification can provide additional opportunity for utilization of preventive
medical management options for cancer risk modification (Drohan et al., 2012; Guo et al., 2017;
Profato & Arun, 2015; Randall & Pothuri, 2016; Snow, 2014). Nair et al. (2015) reports, “The
identification of BRCA mutation carriers, coupled with risk reduction strategies, has been shown
to lower the incidence of both breast and ovarian cancer, as well as cancer specific and allcause mortality” (p. 119). Meaney-Delman and Bellcross (2013) specify that guidelines from the
NCCN comprise the most comprehensive, current, and widely utilized cancer risk reduction
recommendations. Strategies for breast cancer risk reduction include the following: (a) breast
self-awareness; (b) lifestyle factor modification (e.g., alcohol consumption, breastfeeding,
exercise, combination hormone replacement therapy use); (c) once to twice yearly clinical
breast examination; (d) once yearly mammography and breast magnetic resonance imaging
(MRI); (e) use of a risk-reducing medication from the aromatase-inhibitor or selective estrogenreceptor modulator categories; (f) bilateral mastectomy; (g) bilateral salpingo-oophorectomy;
and (h) clinical trial participation (NCCN, 2019a).
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Particularly in women at-risk for hereditary breast cancer, the use of specific medical
management options can lead to breast cancer reduction and improved survival rates (MeaneyDelman & Bellcross, 2013). Multiple studies have demonstrated that bilateral prophylactic
mastectomy provides a 90% breast cancer risk reduction (Johns, Agarwal, Anderson, Ying, &
Kohlmann, 2017). Further studies indicated a reduction of ovarian cancer by 86% when a riskreducing bilateral salpingo-oophorectomy was performed, with an additional decrease in breast
cancer risk when this surgical procedure was performed prior to menopause (Johns et al., 2017;
Randall & Pothuri, 2016). Although women may initially be counseled by a geneticist, surgeon,
or oncologist regarding risk-reducing recommendations, it is important that health care providers
are familiar with guidelines and subsequent revisions for breast surveillance, medication, and
surgical opportunities in this at-risk group.
A primary objective for this EBP project coincides with that of ACOG, “With increased
awareness of the importance of family history as a screening tool and of the values of
preventive measures and increased surveillance, there is hope for improved outcomes” (ACOG,
2018, p. 1). It is suggested that following the proposed EBP protocol, including the use of a
breast cancer genetics referral screening tool, will provide women who are cared for at this
Ob/Gyn practice with more consistent and thorough assessment of their individual risk of
hereditary breast cancer regardless of the provider they are seeing. Women who are then
determined to be at high risk for hereditary breast cancer can be offered further management
options, to include genetic counseling with possible testing, allowing for a high level of care
consistent with current organization and society guidelines.
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CHAPTER 2
EBP MODEL AND REVIEW OF LITERATURE
Evidence-based Practice Model
Overview of EBP Model
Evidence-based practice encompasses the pursuit to provide the greatest quality of
health care based on the highest level of knowledge available (Doody & Doody, 2011).
Professional expertise and patient predilection are additional components of EBP (Schmidt &
Brown, 2015). EBP models facilitate the integration of this evidence into clinical practice with
the objectives of optimal or improved patient outcomes (Doody & Doody, 2011). The Iowa
Model of Evidence-Based Practice to Promote Quality Care, hereafter referred to as the Iowa
Model, was utilized for structuring this EBP project. Founded upon Martha Roger’s Diffusion of
Innovations theory, the Iowa Model was originally created in 1994 by Marita G. Titler and fellow
nurses at the University of Iowa Hospitals and Clinics (Iowa Model Collaborative et al., 2017).
The Iowa Model has been revised several times, with the most recent update occurring in 2015
(Iowa Model Collaborative et al., 2017). This model is often the foundation for implementing
new guidelines into an organization to enhance the quality of care and therefore was
determined to be ideal for providing direction for this EBP project of a protocol implementation at
an Ob/Gyn practice (Iowa Model Collaborative et al., 2017; Schaffer, Sandau, & Diedrick, 2013).
With the most current revision, the Iowa Model Collaborative et al. (2017) delineates the
model’s seven steps, in addition to three opportunities to determine if the process can occur
based on necessary relevance and evidence to pursue the change. The first step is to choose
the topic, which is often generated by an update in knowledge or a current obstacle in ideal
patient care provision. The focus or problem is identified during the second step. The PICOT
format is often used to provide further clarity during this task. After completion of these initial
two steps, one must pause and determine if the focus or problem is a sufficient enough of a
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concern to pursue. If it is determined to be adequate at this initial checkpoint, the process
continues; if it isn’t, another topic should be considered.
Choosing team members is the third step. Team members will collaborate with creating
and integrating the EBP change and should include key stakeholders (Doody & Doody, 2011;
Iowa Model Collaborative et al., 2017). The team will then initiate the fourth step, which is
obtaining and evaluating the evidence. An appraisal tool is chosen to classify the quality of the
information collected. Upon reviewing the appraised evidence, the second occasion and
checkpoint arises to consider if the evidence supports the change. If it does reinforce EBP,
continuation to the following step can occur; if it doesn’t, further research efforts are necessary.
The fifth step is the generation and trial performance of the EBP change (Iowa Model
Collaborative et al., 2017). This pilot process is unique amongst the EBP models and includes
evaluating data and reporting the change’s effectiveness. The third opportunity occurs to
decide if this change should be approved for continued use. If it is supported, the final
checkpoint completion permits the last two steps to be initiated; if it isn’t, it is necessary to
consider different procedures in which to implement the change.
During the sixth step in the Iowa Model, the EBP change is permanently established
(Iowa Model Collaborative et al., 2017). This step requires strategies to manage and reinforce
these changes. Concluding with the seventh step is providing communication about the change
outcome. This can range from providing education and updates at a staff meeting, to more
widespread endeavors, such as a conference presentation or a journal publication (Iowa Model
Collaborative et al., 2017). This final process of the Iowa Model promotes further advancement
of EBP.
Application of EBP Model to DNP Project
Using the Iowa Model to guide this EBP project (see Appendix A), the first step of topic
identification was initiated when it was observed that women at an Ob/Gyn practice were not
consistently being assessed for their risk of hereditary breast cancer and then as appropriate,
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being offered a referral for genetic services. The topic chosen became hereditary breast cancer
risk assessment. For the second step, the PICOT format was applied. In women cared for in
an obstetrical and gynecological practice (P) how does utilization of a breast cancer genetics
referral screening tool (I), as compared to the current practice of collecting and reviewing family
history in patients’ electronic medical record (C), promote women at increased risk for hereditary
breast cancer to be identified and referred for genetic counseling (O) within a twelve-week time
frame (T)? This topic was then determined at this initial checkpoint to be an appreciable
concern at this Ob/Gyn practice for this process to proceed.
Choosing team members for this EBP change was the third step. The key stakeholders
were the health care providers at this practice, consisting of CNMs, NPs, and physicians. The
managers, medical assistants (MA), and registration representatives (receptionists) are also
integral representatives of this team. Epic is the electronic medical record (EMR) system used
in this health care practice and an Epic information technologist has been recruited for
assistance with this EBP project. A literature search was performed during the fourth step to
evaluate the current EBP pertaining to this topic. Multiple databases were employed with a
variety of systematic reviews and studies obtained and reviewed. The level and quality of these
pieces of evidence was established. The reviewed literature consistently supported the urgency
of assessing women’s risk for hereditary breast cancer. Upon identification of women at-risk for
hereditary breast cancer, genetic counseling promotes early detection of BRCA gene mutations
along with the ability to review medical management options. At this checkpoint, the evidence
reinforced both the focus and the need for this EBP project and supported its continuation.
Protocol development was the catalyst for the fifth step. This was anticipated to be one
of the most time consuming portions of this process. The protocol specifically designated the
process for evaluating women’s risk for hereditary breast cancer and clarified each team
member’s role in this endeavor. Team members were educated on their specific responsibilities
for the protocol utilization through individual and/or group meetings. Those who are unable to
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attend the meetings were contacted via email and provided protocol and specific role
information with request for feedback and questions. A web-based version of the breast cancer
genetics referral screening tool (B-RST™) was used to determine if a patient was at-risk for
hereditary breast cancer. To allow for both convenience and timeliness, the Epic charting
system contained a hyperlink within the flowsheet portion of the EMR that went directly to the BRST™ website. Within this fifth step was implementation of the protocol with data collection.
Prior to protocol implementation, data for the total genetics and High Risk Breast Clinic referrals
ordered by each of the providers at this Ob/Gyn office was obtained for the 12-week time period
of September 24, 2018 through December 14, 2018. To evaluate the pilot portion of this
change process, this data was compared to the number of genetic and High Risk Breast Clinic
services referrals provided by each health care provider and in total. Each week a report was
run through the EMR in order to evaluate the adherence of the protocol implementation. Data
synthesis allowed the opportunity to obtain feedback regarding each health care provider’s use
of the tool. In addition, team member evaluation was requested in person and/or by email for
communication about what was working effectively and/or not as well, in order to enhance
progression of this change. Any modifications for improving the efficacy for this protocol and
augmenting the likelihood for a successful change were then communicated to each team
member through meetings and/or emails. During this last checkpoint of the process, data
analysis coupled with team member feedback aided in deciding if the process for change was
effective and could continue for the planned twelve weeks.
The sixth step incorporated continued use of the protocol with the goal of long-term
implementation. Consideration for planning efforts to maintain this change in practice occurred
simultaneously with periodic monitoring for consistency of tool use dependent upon each team
member’s role. As included in the previous step, team member feedback was requested every
two weeks; this occurred more frequently if protocol compliance was noted to have decreased.
Team members continued to be updated if any portions of the process were altered.
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The seventh and final step was to communicate results of the EBP project to the team
members. Once again, this took place at individual or group meetings and/or through emails.
Additional options for disseminating EBP project results include presenting findings at a local of
national professional organization’s conference and/or a journal publication. With the
conclusion of this step, it will be integral that assessments occur periodically to promote
sustainability of this change remaining an office-based standard of care.
Strengths and Limitations of EBP Model for DNP Project
Prior to and during its application to this EBP project, it was necessary to consider the
strengths and limitations of the Iowa Model. Strengths included that the model was: (a)
thorough with seven detailed steps; (b) structured, although still allowing the flexibility of an
individual approach to the process of change; (c) up to date with recent modifications validated
since 2015; (e) readily available to use with permission; (f) designed with three checkpoints to
determine if continuation of the change is appropriate to further pursue; and (g) unique with step
five’s feature of a pilot process, allowing a trial period with evaluation of the results. Additional
strengths consisted of the ability of anyone from beginner to expert status to use this model, its
application to diverse settings, and feedback from more than 600 individuals who had previously
used this model was provided for the most recent revision (Iowa Model Collaborative et al.,
2017). Several weaknesses were noted, with one being multiple steps having two to nine tasks
recommended to accomplish prior to advancing to the next step. Although a plausible approach
both ways, steps three (build team) and four (assess evidence) seemed best approached in vice
versa order, and this was the approach for this EBP project. Lastly, it would be advantageous
to have further clarification with specific tips for maintaining a successful change in specific
health care settings. Keeping the strengths and weaknesses in consideration, the Iowa Model
best fit the procedure for this EBP project.
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Literature Search
Sources Examined for Relevant Evidence
Search engines and key words. In order to find support for the best practice in
assessing breast cancer risk, a search of the current literature was conducted using six
separate databases, including: Cumulative Index to Nursing and Allied Health Literature
(CINAHL), Cochrane Library, Joanna Briggs Institute EBP Database, MEDLINE via EBSCO,
Nursing & Allied Health Database, and PubMed. Multiple variations of the search terms were
attempted, with the following final key search terms used: (1) “breast neoplasms” OR “breast
cancer;” and (2) “family history” OR genetic OR hereditary OR “high risk” OR inherited OR
predisposition; and (3) apprais* OR “risk assessment” OR tool*, and (4) refer*. Related to the
resource capacity of the Nursing & Allied Health Database, the search terms were limited to: (1)
“breast neoplasms” OR “breast cancer;” and (2) “family history” OR genetic OR hereditary and
(3) “risk assessment,” and (4) refer*. Additional terms not included in the final search were:
BRCA, consult*, counsel*, evaluat*, familial, gene* refer*, HBOC, model, predict*, and screen*.
Depending on the database searched, these terms were eliminated based on search results
either being too extensive or not contributing additional quantity of evidence obtained.
Inclusion and exclusion criteria. Inclusion criteria consisted of: (a) female population,
(b) published in the English language, (c) published between (January) 2012 through (July)
2019, (d) scholarly/peer reviewed journals, and (e) academic journals. Publications were
excluded for any of the following criteria: (a) the study population was women with a current or
prior diagnosis of breast cancer, (b) the study focus was on a breast cancer tumor test, gene
sequencing, or a recurrence score assay, (c) the study population included those with at least
one family member with a known BRCA gene mutation, (d) the breast cancer risk and/or referral
tool was used at the time of mammography services only to determine if a woman qualified for a
breast MRI, (e) the focus was explicitly on care provided by geneticists or other specialists
providing cancer genetic services, or specific services provided at a High Risk Breast Clinic, (f)
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the focus was risk for cancers other than breast, (g) the emphasis was on individual breast
cancer risk perception, or (h) the risk model was used for determining appropriateness of
chemoprevention.
Search results. Within CINAHL, the search yielded 28 pieces of evidence with 9
reviewed and 1 accepted without duplicates. Within the Cochrane Library, 104 were yielded
within the following categories: 85 Cochrane reviews and 19 Cochrane protocols; 12 were
reviewed, and 2 were accepted with 1 duplicate. Within the Joanna Briggs Institute EBP
Database, 28 were yielded with 5 reviewed and 1 accepted without duplicates. Within
MEDLINE via EBSCO, 153 were yielded, with 23 reviewed, with 3 accepted with 2 duplicates.
Within Nursing & Allied Health Database, 372 were yielded with 31 reviewed and 3 accepted
without duplicates. Within PubMed, 144 were yielded with 20 reviewed, with 7 duplicates, and
without new evidence discovered. In addition, Google Scholar and Trip Medical Database were
accessed several times with the inability to limit the final search results to less than 400
resources.
Within these six databases, a total of 829 pieces of evidence were obtained. With the
inclusion and exclusion criteria established, 100 abstracts were reviewed, and subsequently 25
pieces of evidence were then read in their entirety. Seven duplicates were discovered amongst
the different databases. Fifteen pieces of evidence were excluded due to weak support of this
EBP project, resulting in a total of 10 pieces of evidence for final review. See Table 2.1 below
for the results of the literature search.
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Table 2.1
Literature Search
_______________________________________________________________
Database

Yielded

Duplicates

Reviewed

Accepted

_______________________________________________________________
CINAHL

28

0

9

1

Cochrane
Reviews
Trials

85
19

1

12

2

JBI

28

0

5

1

MEDLINE

153

2

23

3

Nursing & Allied
Health

372

0

31

3

PubMed

144

7

20

0

Total
829
10
100
10
_______________________________________________________________
Note. CINAHL is the Cumulative Index of Nursing and Allied Health Literature.
JBI is the Joanna Briggs Institute.

Appraisal of Relevant Evidence
Appraisal tool utilization. In order to support changes within health care based on
EBP, it is essential that current evidence is appraised. This appraisal consists of ranking the
level and quality of evidence with evidence hierarchies (Long, 2015). Higher levels and/or
qualities of evidence provide a solid foundation for change. The Johns Hopkins Nursing
Evidence-Based Practice Model is a model focused on the application of EBP and nursing.
Multiple tools are available for evidence evaluation along with directing the EBP process (Dang
& Dearholt, 2017). Both the level and quality ratings for this EBP evidence appraisal were
ranked utilizing the 2017 edition of the Evidence Level and Quality Guide from the Johns
Hopkins Nursing Evidence-Based Practice (see Appendix B). This tool categorizes five levels of
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evidence between Level I through Level V with a hierarchy approach and are further described
as follows (Dang & Dearholt, 2017). Level I contains the highest level of evidence and is
comprised of experimental studies, such as a randomized controlled trial (RCT). Systematic
reviews of multiple RCTs and explanatory mixed methods using a level I quantitative studies are
also included in this category. Level II includes quasi-experimental studies, systematic reviews
of RCTs and/or quasi-experimental studies, or explanatory mixed methods using a level II
quantitative study. Level III consists of non-experimental studies, including systematic reviews
of multiple study types, exploratory or qualitative studies, and explanatory mixed methods using
a level III quantitative study. Level IV encompasses evidence-based guidelines from
professional medical societies or groups within these organizations, including organizationspecific best-practice recommendations. Level V incorporates evidence based on background
and experience and does not include research. This includes a combination of case reports,
professional expert opinions, integrative and literature reviews, and programs focusing on
economics or quality improvement.
It is noteworthy that this Evidence Level and Quality Guide tool is more rigorous in
ranking levels of evidence by differentiating between approaches for studies or evaluation of
studies, such as explanatory mixed and systematic reviews. Other appraisal tools group entire
categories together. For example, one particular evidence hierarchy organizes and ranks
systematic reviews and guidelines for EBP at the uppermost level of evidence without
differentiating between types of studies utilized for each of these (Long, 2015).
This appraisal tool also provides guidance for rating the quality of each level of evidence
with specifications for quantitative and qualitative studies (Dang & Dearholt, 2017). Evidence
with higher quality ratings are considered more substantial for use with proposed EBP changes.
The quality ratings for this tool are as follows: A, high quality; A/B, high/good quality; B, good
quality; and C, low quality (Dang & Dearholt, 2017). Each of these rankings has specific
qualifications depending on which level of evidence is being appraised. For quantitative studies,

HEREDITARY BREAST CANCER PROTOCOL

20

high quality evidence incorporates: (a) results that are applicable to similar or other populations
along with being compatible with other studies and/or current evidence, (b) a study population
considered to be of adequate measure, (c) sufficient control, and (d) an accurate and detailed
literature search to support recommendations (Dang & Dearholt, 2017). Using Dang and
Dearholt’s (2017) specific terminology, qualitative studies with a high quality or high/good quality
exhibit the following: (a) transparency, (b) diligence, (c) verification, (d) self-reflection and
scrutiny, (e) participation-driven inquiry, and (f) insightful interpretation (p. 1). Table 2.2 below
summarizes the evidence summary.

Table 2.2
Evidence Summary
____________________________________________________________________________
Level

Included

Quality

Design

____________________________________________________________________________
I

2

A (1)
B (1)

Systematic Review of RCTs (1)
Randomized Controlled Trial (1)

II

1

B (1)

Controlled Trial without Randomization (1)

III

5

IV

2

A (2)
A/B (1)
B (2)

A (1)
B (1)

Pilot Exploratory Study (1)
Demonstration Project (1)
Qualitative Study (1)
Systematic Review of Combination of Studies (1)
Cross-Sectional Study (1)
Professional Organization Clinical
Practice Guideline (1)
Evidence Summary (1)

V
0
____________________________________________________________________________
Note. The Evidence Level and Quality Guide from the Johns Hopkins Nursing Evidence-Based
Practice was used to appraise the evidence. (Dang & Dearholt, 2017)
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Levels of Evidence
Using the Evidence Level and Quality Guide from the Johns Hopkins Nursing EvidenceBased Practice Model, ten pieces of evidence were appraised encompassing four of the five
levels of evidence. Level I evidence included one systematic review of RCTs and one
randomized controlled trial. One controlled trial without randomization met the criteria for level
II. Level III encompassed the majority of the evidence and consisted of one of each of the
following: (a) pilot exploratory study, (b) demonstration project, (c) qualitative study, (d)
systematic review of a combination of studies, and (e) cross-sectional study. Level IV included
one evidence summary and one professional organization clinical practice guideline. There
were no level V pieces of evidence. For quality ratings, four pieces of evidence were graded A,
one was A/B, and five received a B. See Appendix C for the Evidence Data Table.
Level I evidence. Level I evidence included one systematic review of RCTs and one
randomized controlled trial. Hilgart, Coles, and Iredale (2012) performed an updated systematic
review of RCTs for the Cochrane Database focusing on the impact of breast cancer risk
evaluation and genetic services. Studies included women and men across the lifespan who
were: (a) at-risk for breast cancer related to cancer family history, (b) without a personal history
of breast cancer, and (c) without a personal known BRCA gene mutation. Five additional RCTs
were appraised from the 2007 review to bring the total to eight, with N = 1973. Outcomes were
divided into three categories: (1) Methods for performing risk evaluation; (2) approaches for
providing genetic health care; and (3) differences between risk evaluation performed by a
genetic specialist or a non-genetic specialist. The studies revealed that genetic services
provided: (a) a decrease in cancer anxiety and enhanced emotional well-being; (b) increased
personal risk perception accuracy and knowledge concerning breast cancer and genetic
services, and (c) overall satisfaction with use of genetic services. The authors concluded that
hereditary breast cancer risk assessment is an essential process to be performed for
determining appropriateness of genetic services referrals, with the benefits of genetic services
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considered to outweigh the harms. Strengths of this systematic review include an extensive
search strategy, the inclusion and exclusion criteria were precisely presented, high levels of
evidence were reviewed, the sample size was adequate, and the methods for determining
biases in the RCTs were thoroughly described and applied. Weaknesses were the omission of
summarizing strengths and weaknesses of the studies, potential bias during the literature
search since terms were not consistent from one database to another, and the inability to
perform a meta-analysis to determine an effect size due to diversification amongst the RCTs.
This systematic review was provided a quality rating of A due to the ability to generalize results,
the large sample size, and conclusions based on EBP.
The second level I item of evidence was a RCT performed by Kaplan et al. (2014). This
RCT was comprised of women ages 40 to 74 years old without a previous history of breast
cancer receiving health care at two U.S. metropolitan primary care medical offices. The
population size was sufficient with N = 1235, with the intervention group (n = 580) and control
group (n = 655) being randomized after baseline phone interviews using statistician-developed
sequence codes. The intervention was use of the BreastCARE web-based tool, which stratified
breast cancer risk by simultaneously using the: (a) Referral Screening Tool, (b) Gail Model, and
(c) Breast Cancer Surveillance Consortium risk model. The system for obtaining data was: (1)
Utilization of the BreastCARE appraisal tool in the intervention group; (2) a one to two week
post-visit phone survey, and (3) a six month post-visit EMR review. Outcomes were that use of
the BreastCARE tool increased: (1) Patient-provider breast cancer risk conversations with OR
2.07, 95% CI [1.34, 3.20], (2) patient-provider risk reduction conversations with OR 4.78, 95%
CI, [2.90, 7.89], (3) referrals for genetic services for those at increased risk with OR = 5.32, 95%
CI, [2.21, 12.8], and (4) EMR charting regarding each of these activities. Overall, this RCT
demonstrated that use of a web-based risk evaluation tool enhanced health care providerpatient discussions about breast cancer risk and medical management options. Areas of study
weakness encompassed the potential differences between the two office settings possibly
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causing a decreased ability to generalize findings; potential biases with individual-reported
information; and, the need to address health care provider challenges with performing
hereditary breast cancer risk assessment consistently due to omission of this activity in some of
the intervention patients. The sample population was sufficient and data for multiple objectives
were collected; however, since statistical findings of this RCT did not include information
regarding instrument reliability and validity and potentially lacking the ability to generalize
results, it is provided a quality rating of B.
Level II evidence. Level II evidence consisted of a controlled trial without randomization
performed by Baer et al. (2013). The study population was new or established female and male
patients between 18 to 75 years old, without a family history of cancer documented in their
EMR, presenting for annual examinations within five urban academic primary care medical
practices. The sample sizes were adequate with the intervention group consisting of patients
from three of the practices (n = 996) and the control group from the other two practices (n =
637). The study’s purpose was to determine the practicability of implementing the Your Health
Snapshot web-based hereditary breast and colon cancer risk assessment tool in the primary
care setting. The principal outcome was new documentation of cancer family history in the
EMR within one month of the patient visit. The secondary outcome was new cancer screening
test notices initiated within one month of the visit by health care providers for those with an
increased risk for breast or colon cancer. Data were obtained from the intervention group
completing the risk appraisal tool prior to their appointment with review of EMR records one
month after visits for both groups. For the first outcome, those in the intervention group had a
far greater likelihood compared to the control group of having new EMR charting regarding the
presence of cancer family history (10.6% vs. 0.8%, p = 0.0003) and an adjusted OR of 15.9,
95% CI, [3.5, 72.1]. For the second outcome, there was no significant statistical significance for
new cancer screening test notices for those with an increased risk for hereditary cancer
provided by health care providers between the intervention and control groups at eight vs. zero

HEREDITARY BREAST CANCER PROTOCOL

24

provided respectively. Participation in the post-appointment telephone survey was suboptimal
with the intervention and control groups at 46.1% and 20.2% compliance respectively.
Additional limitations of the study were: non-randomized groups, poor overall participation with
only 10.3% of those eligible participating, differences in demographic characteristics between
the two groups, and instrument reliability and validity was not provided. Conclusions were
based solidly on results, as use of this web-based risk evaluation tool demonstrated an overall
increase in documentation of cancer family history. Due to the lack of instrument reliability and
validity, poor participant response rates, and potentially lacking the ability to generalize results
related to demographic differences, this study was provided a quality rating of B.
Level III evidence. The majority of evidence appraised was Level III evidence, with one
each of the following: exploratory pilot study, demonstration project, qualitative study,
systematic review of a combination of studies, and cross-sectional study. Anderson et al.
(2015) implemented an exploratory pilot study with low income African American and Hispanic
women ages 25 to 69 years old, without a personal history of breast cancer, presenting for
annual examinations at two federally assisted medical institutions in the Midwest. The purpose
of this study was to evaluate the development and utilization of a breast cancer risk appraisal
policy within a practice with multiple ethnicities. In a study population of N = 237, prior to
examination with the health care provider, the following was collected: (a) risk factor information,
(b) baseline survey, and for those consenting, (c) a breast cancer risk evaluation using the BC
Risk Screening (BRS) web-based tool. This tool simultaneously uses the following to provide a
risk assessment: (1) Claus, (2) modified Gail, and (3) pedigree assessment tool. The majority of
the population (n = 207, 87.3%) chose to be informed of their breast cancer risk assessment
results with an increased likelihood with women ages 40 to 49 years old with OR 5.4 (95% CI,
[1.09, 26.67]) and from 50 to 69 years old with OR 7.99 (95% CI, [1.47 - 43.44]). Successful
use of a web-based tool in the office setting to efficiently perform the risk appraisal was
evidenced by the high rate of BRS tool use noted in this population, with consideration of health
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care provider barriers of time restraints and/or lack of breast cancer risk knowledge. Limitations
were the: (1) Inability to obtain additional explanations from the women who declined receiving
their risk information; (2) potential lack of generalizability with women from other ethnic
backgrounds; and (3) potential recruitment bias as women arriving for their annual examination
presumably placed more of a priority on their health. The researchers concluded that
implementing a web-based tool, as recommended by the USPSTF 2013 recommendations,
enhanced performance of a breast cancer risk appraisal in the office setting. Furthermore, this
process occurred without disturbance of the normal workflow in a primary care practice. This
exploratory pilot study was provided a quality rating of B due to the small sample size, omission
of information regarding the reliability and validity of the BRS tool, and the potential limitation to
generalize results to women of different ethnicities.
Brannon Trexler et al. (2014) demonstrated utility of the breast cancer genetics referral
screening tool (B-RST™) through a demonstration project. The sample population was
primarily minority and low-income women ages 14 to 85 years old without a personal history of
cancer obtaining health care at one of six participating public health departments in a southern
U.S. state. The participant population was adequate with N = 2159. The staff was educated
through multiple methods on hereditary breast and ovarian cancer (HBOC) syndrome and how
to use the B-RST™. In order to identify and manage appropriate at-risk women, the B-RST™
was then used during medical history collection prior to the health care provider examination.
The objectives of this project were: (1) Integrating the B-RST™ within a minority population to
recognize women with increased HBOC risk; (2) assisting with the health care management of
those having positive B-RST™ results; and (3) educating staff about cancer genetic topics with
the goal of accurate utilization of the B-RST™. Validity of the B-RST™ occurred by comparing
its use to multiple models with four-generation cancer family histories. Sensitivity was
determined to be 89.4% and specificity was 90.1%. For the first objective, out of the 2159
participants: (a) 130 (6.0%) had positive B-RST™ results, (b) 110 (84.6%) from this group of
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women then consented to be contacted, (c) 67 (60.9%) provided cancer family history
clarification, (d) 47 (42.7%) of these women were successfully contacted and determined to be
appropriate for testing per current medical society guidelines, and (e) 14 (12.7%) performed
cancer genetic testing, with one (7.1%) woman being diagnosed with a BRCA2 gene mutation.
She was guided through medical management strategies, which then completed the second
objective. The third objective was achieved by an increase in staff knowledge as demonstrated
by improved post-activity test results. One of the limitations was that participants were not
aware a multi-generational cancer family history was going to be requested at their
appointment, with potential inaccuracies likely causing both false negative and false positive BRST™ results. Also, the reason(s) why participants declined follow up (n = 20) after receiving
positive B-RST™ results was not collected. The researchers concluded that their project had
favorable outcomes, especially with evaluation of breast cancer risk in a group of minority
women who likely did not have this assessed before. This study was given a quality rating of A
for the large sample population, inclusion of the tool’s sensitivity and specificity, and conclusions
based on EBP.
Christianson et al. (2012) presented their qualitative study of use of a risk assessment
tool by health care providers from a variety of specialties within a community-based medical
system on the East Coast. The sample population (N = 16) consisted of 14 physicians and two
mid-level providers from nine medical practices within the same county. The demographics of
the sample population were primarily males (n = 12) and Caucasians (n = 12). This information
was not provided for both of the mid-level providers. The purpose of this study was to
determine health care provider perceived challenges with integration of a risk stratification tool
in order to resolve these factors and improve its future utilization. The participants attended one
of the three focus meetings in which nine questions were discussed regarding the impending
use of the MeTree web-based risk assessment tool at a local oncology center. This tool
evaluates inherited risks for breast and colon cancers, in addition to thrombophilia disorders.
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Five themes were recognized: (1) Current methods utilized for evaluating risk of medical
conditions, (2) barriers associated with obtaining and using family health histories, (3)
challenges associated with applying family history to individualized health care strategies, (4)
obstacles with performance of the MeTree tool at the oncology center, and (5) medical and
educational needs. Although these themes were noted repetitively, the researchers reported
that saturation was not attained related to the small sample population. Validity and reliability
were applied by performance of the following for both of the discussions: (a) use of a topic
template guide, (b) being led by the same individual, (c) producing an audio recording, (d)
obtaining written documentation including non-verbal elements, and (e) providing a manuscript
from the audio recording. For interpretation of the data, this information was coded and
analyzed both manually and with the use of a computer software program. It is unclear if there
was a method used to verify the credibility of the data evaluation with this sample population.
Considering the small sample size and subsequent lack of saturation, the quality rating of A/B
was provided for the inclusion of distinct methods for supporting this qualitative study’s purpose
and incorporating a perceptive analysis pertinent to available evidence.
Nelson et al. (2014) performed a systematic review of multiple study types as an update
to the 2005 USPSTF recommendation for hereditary breast cancer risk evaluation and genetic
services utilization. The population of interest was women across the lifespan provided health
care in locations similar to the U.S. without a personal history of a BRCA gene mutation or
BRCA-related cancer(s). For studies included in this review (N = 27), 16 were new for this
update and included systematic reviews, RCTs, cohort, and case-control studies. A variety of
interventions were studied: (a) five risk models/tools; (b) risk perception and cancer worry; and
(c) tests, meds, and surgeries to decrease risk of BRCA-related cancers. The outcomes of
concern evaluated potential benefits and harms in three areas: (1) BRCA risk evaluation
model/tool use, (2) genetic services results, and (3) BRCA management options for malignancy
and mortality reduction. Outcomes were based on study findings with a best practice
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recommendation presented to weigh individualized benefits, harms, and risks when assessing
hereditary breast cancer risk, referring for genetic services, and/or offering medical
management to decrease cancer risk. Sensitivity between five referral and four risk models
were compared with the Referral Screening Tool reported as having high levels of sensitivity
and specificity. Although the authors were unable to perform a quantitative meta-analysis due
to study heterogeneity, this systematic review was rated at an A quality due to the search
strategy and findings from this systematic review being comprehensive with outcomes based on
EBP.
Solomon, Whitman, and Wood (2016) performed a cross-sectional study of women with
an average age of 63 years old receiving services at a mammography center in a Northeastern
U.S. city. The sample population (N = 499) was sufficient. A questionnaire was completed at
the time of mammography services. The recommendation for reviewing additional breast
medical management options, such as genetics services referrals, were then based on the use
of the: (1) ACS and NCCN screening guidelines for colon cancer, (2) Claus model for breast
cancer risk estimation, and (3) breast cancer genetics referral screening tool (abbreviated RST
by the authors). This study’s aim was identification and comparison of individuals qualifying for
cancer genetic services based on either a limited/first-degree cancer family history or a more
comprehensive/first and second-degree family histories in order to determine appropriate
candidates for genetic services referrals. Out of the 499 participants: (a) 71.9% (N = 359) had a
family history of breast or colon cancers in a minimum of one family member; (b) 56.5% (n =
282) had a family history of breast cancer in a minimum of one family member; (c) 24.6% (n =
123) had a family history of colon cancer in a minimum of one family member; and (d) 13.2% (n
= 66) had a family history of both breast and colon cancers. Based on cancer family history, the
Claus Model and the RST were then performed to determine breast cancer risk, and ACS
guidelines were applied to assess risk for colon cancer. The Claus Model recognized 3.6% (n =
18) as being at-risk for breast cancer; with only 28% (n = 5) of these 18 women classified at-risk
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when the limited/first-degree cancer family history was taken into consideration. Similar results
were discovered using the RST, with 1.8% (n = 9) of the women being considered appropriate
for genetic services referrals; out of these nine women 77% (n = 7) were identified as being
candidates for genetic services referrals with use of the limited/first-degree cancer family
history. For the colon cancer risk evaluation, 12% (n = 62) qualified for increased risk screening
procedures following ACS recommendations; whereas, 81% (n = 50) of the 62 women were
recognized with limited/first-degree family history use. Limitations of this cross-sectional study
were that selection bias was a potential due to the location of a mammography facility for
questionnaire distribution, the lack of a description of the model/tool reliability and validity, and
data collection occurred > one decade prior (2001 through 2002). The concluding factor drawn
from this study highlighted the importance of using a risk screening tool, rather than exclusively
reviewing first and second-degree cancer family history, in order to provide an accurate
hereditary cancer risk evaluation. With the limitations taken in consideration, this crosssectional study was provided a quality rating of B due to an adequate sample size and overall
results applicable to practice.
Level IV evidence. Appraisal of Level IV evidence consisted of one professional
organization clinical practice guideline and one evidence summary. Based on evidence-based
research findings, Berliner, Fay, Cummings, Burnett, and Tillmanns (2013) updated the 2007
National Society of Genetic Counselors (NSGC) clinical practice recommendations. Evidence
was included from multiple professional organizations with the majority of the studies and
articles cited focusing on hereditary breast cancer risk assessment models and BRCA genetic
mutations. Six concise best practice recommendations were specified as follows: (1) Consult
guidelines to determine if a woman is a candidate for cancer genetic testing and provide
individualized health care risk-reducing strategies; (2) consider BRCA and other applicable gene
mutations; (3) perform a cancer risk evaluation utilizing an assessment model to determine
subsequent approach for health care management; (4) determine medical management options

HEREDITARY BREAST CANCER PROTOCOL

30

based on cancer family history, assessed risk, medical expertise, and outcome of genetic
testing; (5) arrange referral to a genetics professional to provide resources to support
educational and emotional needs; and (6) explain current, multi-faceted consequences of
genetic testing. Each recommendation was supported by EBP. This best practice guideline is
both advantageous and easily applicable, with it being provided a quality rating of B due to the
omission of information regarding biases and evidence levels, and related to it being a six year
old guideline due to be updated.
Obeid (2017) authored a Joanna Briggs Institute Evidence Summary focused on familial
breast cancer. References used for this summary encompassed two Cochrane Database
systematic reviews, evidence from the National Institute for Clinical Excellence, and one each of
the following: meta-analysis, RCT, cross-sectional observational study, epidemiological study,
and a literature review. Regardless of practice specialty, this summary is applicable for any
health care providers involved in primary, secondary, or tertiary care of women with a family
history of breast cancer. Best practice recommendations were specified for: (1) Patient-focused
care; (2) cancer family history and provider referral; (3) screening; and, (4) genetic services.
These were subsequently graded by the author, with each receiving a grade B. Concise
instructions for these best practice recommendations were provided. Most pertinent to this EBP
project were suggestions for: (a) promoting patient-provider discussion about breast cancer risk
that respects a patient’s personal decisions; (b) creating and providing handouts on pertinent
breast cancer risk topics; and, (c) producing protocols for performing genetic services referrals.
A limitation was that information was not provided in regards to the process of reducing biases.
This piece of evidence is rated as an A/high quality based on the up-to-date nature of the
summary, the high levels of evidence used, and its broad applicability.
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Construction of Evidence-based Practice
Synthesis of Critically Appraised Literature
Within the evidence, several challenges were presented with enhancing care by using a
cancer risk evaluation model or tool. It can be time consuming to accurately identify and
reassure those at low risk for hereditary breast cancer, while informing those who are at-risk
about medical management options and promoting active involvement in their health care
(Anderson et al., 2015; Hilgart et al., 2012; Solomon et al., 2016). The lack of importance
individuals may perceive about their cancer family history, coupled with inaccuracies of
reporting this history, may impede the accuracy of risk appraisal results and consequently the
management of these results (Baer et al., 2013; Brannon Trexler et al., 2014). Additional
barriers of risk appraisal tool utilization consisted of: (a) time restraints; (b) health care provider
knowledge and confidence limitations; (c) necessity for specific guidelines to direct care; (d)
communication limitations; (e) legal responsibilities, and (f) resources restraints, including
availability of health care providers to perform genetic counseling (Christianson et al., 2012).
Another challenge encountered is the variance between different medical professional
organization’s recommendations for qualifications for genetic services (Berliner et al., 2013).
Although these differences may be minimal, they can create confusion and potentially a lack of
consistency in this area of health care. It is important to be knowledgeable about these factors
in order to identify methods to overcome them.
Regardless of the type of model or tool utilized for the process of hereditary breast
cancer risk evaluation, positive consequences for both health care providers and patients were
reported. A specific recommendation that guides the focus of this EBP project is presented by
Berliner et al. (2013), which highlighted that health care providers have the flexibility and
responsibility of choosing which risk appraisal tool is best for their practice. A risk appraisal tool
demonstrating ease of use was important for gaining health care provider support of its
implementation into routine practice, while it enhanced more thorough documentation of cancer
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family history, understanding of results, and conversations regarding this history (Anderson et
al., 2015; Baer et al., 2013). Use of the RST improved accuracy of identifying and appropriately
educating individuals at-risk for hereditary breast cancer (Obeid, 2017; Solomon et al., 2016).
Using a family history tool to assess cancer risks supported communication about these risks
between the provider and a patient and consequently guided management options (Berliner et
al., 2013; Christianson et al., 2012; Kaplan et al., 2014). Beneficial outcomes of appropriate
breast cancer risk evaluations include perceived individual benefits and enhanced satisfaction
with counseling (Hilgart et al., 2012; Obeid, 2017) as well as decreased levels of worry after
receiving genetic counseling (Nelson et al., 2014). The evidence appraised extensively
supports incorporating a hereditary breast cancer risk evaluation tool into health care practice.
Best Practice Model Recommendation
The Best Practice Model for answering this EBP project’s PICOT statement was to have
women perform a B-RST™ evaluation at their routine gynecological examination and/or new
patient appointments within the Ob/Gyn practice. This assessment occurred at the beginning of
their appointment, prior to their health care provider seeing them. The B-RST™ was chosen
due to support provided by the USPSTF related to its ease of use by both patients and health
care providers, in addition to having received the highest quality rating (Bellcross, Hermstad,
Tallo, & Stanislaw, 2019; Nelson et al., 2019). Furthermore, this tool was either utilized or
evaluated in three of the pieces of evidence appraised with positive feedback regarding its use,
in addition to high levels of sensitivity and specificity documented (Bellcross et al., 2019;
Brannon Trexler et al., 2014; Nelson et al., 2014; Solomon et al., 2016). The Best Practice
Model with use of the B-RST™ helped answer this EBP project’s clinical question by providing a
reliable and straightforward intervention for hereditary breast cancer risk assessment, data
collection, and comparison to the current practice of cancer family history collection and review
in the EMR.
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CHAPTER 3
IMPLEMENTATION OF PRACTICE CHANGE
At the EBP project setting, the standard practice for establishing if a woman is
considered at-risk for hereditary breast cancer is determined by reviewing the personal and
family medical history sections in the EMR. Prior to completing charting for a patient visit, the
appropriate boxes are expected to be marked in the EMR indicating that specific sections (i.e.,
the history sections which include both personal and family medical histories) have been
reviewed. An underlying assumption in marking these areas of information as reviewed is that a
woman at-risk for hereditary breast cancer is identified and counseled about associated risks
and provided medical management options, with the necessary documentation indicating both
these activities occurred. In addition to the EMR review, select providers within the EBP project
site have their patients complete a personal and cancer family history paper questionnaire,
created by a company that performs cancer genetic analysis. Although this is a method in
which to identify women at increased risk for breast cancer, the intent of utilizing this form is for
the health care provider to personally order genetic testing. It is neither intended for the primary
purpose of identifying women who are candidates for genetic counseling, nor is it amongst the
tools evaluated and recommended by the USPSTF. This lack of uniformity in screening patients
in addition to the current use of tools unsupported by best practice reinforced the necessity for
this EBP protocol to standardize screening women using a validated and efficient tool to
effectively identify high-risk women who are candidates for genetic consultation.
Participants and Setting
The participants for this EBP project included women 18 years or older who sought care
for a routine gynecological examination or a new patient appointment at an Ob/Gyn practice.
The sample population included pregnant women if they were new patients but excluded those
who were established patients receiving continuation of obstetrical care. Individuals with
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impaired mental capacity either related to dementia or developmental conditions (e.g., mental
retardation) were not offered to participate. A personal history of breast cancer was not an
exclusion factor. If a woman returned to the office for repeat care during the project’s time
frame, the screening tool was only utilized once unless a personal or familial cancer history
change occurred.
The EBP project setting was comprised of five office branches of an Ob/Gyn practice
located in two adjoining Northwest Indiana counties. The practice is owned and operated by a
hospital system, which is part of the largest health care system in this region. The
organization’s mission is “…to provide the highest quality care in the most cost-efficient manner,
respecting the dignity of the individual, providing for the well-being of the community and serving
the needs of all people, including the poor and disadvantaged” (Health Care System, nd). The
values of this health care system are community, compassionate care, dignity, quality, and
stewardship (Health Care System, nd). This proposed protocol embraces the mission and
values of this health care system.
Three physicians, three NPs, and three CNMs are currently employed at this Ob/Gyn
practice. Each health care provider sees patients in a variety of the five office locations.
Approximately 400 patient appointments occur weekly. Both insured and uninsured patients are
seen at this practice. The types of insurance plans utilized comprise an extensive amount of
commercial plans, Medicaid, and Medicare coverage.
Pre-Intervention Group Characteristics
The geneticist employed by this health care system provides cancer genetic
consultations at two nearby facilities. Between July 1, 2018 to July 1, 2019, the nine health care
providers at the Ob/Gyn practice referred 30 women for genetic services (H. Hendricks,
personal communication, August 20, 2019). This reported amount of referrals was likely lower
than what actually occurred, as the health care provider may have initially given the geneticist’s
contact information to the patient as they began considering participating in this medical
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management option. If this occurred and the patient then called to schedule a consultation
without updating the health care provider, a formal referral was often missing from the EMR.
Additionally, some of the providers often recommended a referral to this health care system’s
High Risk Breast Clinic for additional breast cancer risk assessment to be performed first, at
which time the routine practice was for genetic services to be reviewed and offered as
appropriate (D. Faitek, personal communication, August 6, 2019). Between the dates of July 1,
2018 through July 1, 2019, a total of 38 referrals were placed to the High Risk Breast Clinic by
the nine providers at this health care practice.
Intervention
An evaluation of eight breast cancer risk appraisal tools was performed by the USPSTF,
with two receiving a quality rating of good, to include the B-RST™ (Nelson et al., 2019). The BRST™ was implemented in several research studies related to being straightforward and not
time consuming to incorporate into practice (Cintolo-Gonzalez et al., 2017). This web-based
tool is freely accessible for use, with the request of crediting the developer for use in this EBP
project, Dr. Cecelia Bellcross (C. Bellcross, personal communication, July 10, 2019). Dr.
Bellcross provided permission for a hyperlink to the B-RST™ to be accessible within the EBP
project site’s EMR (see Appendix D). Due to being amongst the appraisal tools recommended
by the USPSTF and its reported ease of use, the B-RST™ was chosen to screen and identify
women at-risk for hereditary breast cancer.
Upon arrival at the office and being greeted by the registration representative, women
signed in for their appointment and were either provided a pen and customary paperwork or the
tablet to complete the check in process. Next, the patient was called back by the MA to
complete vital sign assessments as well as a review of history information within the EMR.
During this process, the MA accessed the B-RST™ hyperlink within the flowsheet section of the
EMR and completed this assessment with the patient. The risk evaluation result (negativeaverage, negative-moderate, or positive-high) was entered in the flowsheet section by the MA
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for the health care provider to review; in addition, the risk level was marked on the front of the
patient results handout created by the DNP student entitled, Understanding Your Breast Cancer
Genetics Referral Screening Tool (B-RST™) Results (see Appendices E and F). This one page
handout was then placed in the plastic folder that contained a form listing the patient’s name,
date of birth, reason for appointment, and additional patient specific components requested by
each health care provider. After the MA completed the rooming process, this plastic folder was
either placed in a rack outside of the patient’s examination room or given directly to the provider.
The women were then seen by their health care provider as scheduled. The provider reviewed
and discussed the B-RST™ risk results with the patient and subsequently provided the handout
to the patient. These handouts were adequately supplied at each of the offices at the initiation
of the project and then provided to the managers and/or personally delivered to each of the
office locations as needed to ensure the supplies remained adequate. For those women with
negative-moderate or positive-high risk B-RST™ results, their appointment records were
reviewed approximately ten weeks afterwards to verify if a consultation appointment was made
and kept at the High Risk Breast Clinic and/or with the geneticist. Appointments were verified
for the final time on March 1, 2020.
The DNP student ran a weekly report through the Epic EMR to gather data on the
following information: (a) participant initials and medical record number, (b) demographics,
which included age, race, insurance type, and religious preference, (c) appointment type, and
(d) B-RST™ results. In addition, each provider’s daily schedule was evaluated in the EMR for:
(a) candidates eligible for the protocol, (b) B-RST™ performance without results entered in the
flowsheet, (c) B-RST™ performance without qualifying for the protocol, (d) eligibility for a
referral to the High Risk Breast Clinic and/or geneticist, (e) referral provided to the High Risk
Breast Clinic and/or genetic counseling, (f) referral documented but not actually ordered, and (g)
documentation if a referral was declined or had been performed previously. The preceding
information was recorded in an Excel EBP data spreadsheet that was organized by both the
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week of the project and the provider. Printed copies of the weekly reports were kept in a locked
cabinet at the Ob/Gyn office and/or safely secured in a closet at the DNP student’s place of
residence. These reports will be shred upon completion of this EBP project and the Excel files
will be permanently deleted from the DNP student’s home desk top computer.
Planning. As delineated in chapter two, use of the seven steps of the Iowa Model
provided guidance for the development and implementation of this EBP project. Steps one and
two were achieved with the decision to pursue the EBP topic of hereditary breast cancer
assessment, along with the establishment of the PICOT directing the focus of evaluating risk for
identifying appropriate candidates for genetic services referrals. Nearly all staff members at this
Ob/Gyn practice were part of the EBP project team; however, during step three, key team
leaders were identified based on their strengths and heightened interest in this project. The key
team leaders were primarily MAs assigned to work with a specific provider. In accordance with
this step, the protocol process and utilization of the B-RST™ was reviewed with the staff and
their concerns, questions, and recommendations were considered and discussed. Handouts
delineating the process and responsibilities of the health care providers and MAs were provided
and reviewed prior to the EBP protocol implementations (see Appendices G and H).
Step four of the EBP process was completed prior to protocol implementation,
encompassing a comprehensive review of the literature. A total of ten pieces of evidence were
appraised and utilized to support the EBP project and the proposed protocol. Meanwhile, the
fourth step was accomplished by choosing a tool with simple features allowing the staff to obtain
and review results promptly, with the goal of performing an accurate hereditary breast cancer
risk assessment while limiting interference with the normal daily office routine.
For step five, the EBP protocol was implemented, with the steps detailed in the
preceding section entitled “Intervention.” Two weeks into EBP protocol implementation, initial
data and feedback from stakeholders was reviewed and analyzed, which guided the project
manager to make adjustments as necessary to continue this process. Health care provider
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compliance was considered adequate if appropriate use of the tool occurred with at least 75% of
the women who qualified for the protocol. In order to either maintain or improve participation
rate, challenges specific to protocol adherence were discussed with appropriate team members.
Individual compliance rates were calculated weekly by comparing the number of patients eligible
for use of the B-RST™ with those who actually had the tool performed and documented. The
trial portion of this fifth step was an integral part of the process towards achieving favorable EBP
practice model adherence. With the exception of some providers requesting their patients to be
given their results handout prior to them entering the room, it was determined during the pilot
portion that the remaining ten weeks of the EBP project would be completed as initially planned.
During step six, integration of the B-RST™ in this health care setting was determined to
be a proficient method for identification and referral of women at-risk for hereditary breast
cancer in this health care setting. Necessary strategies for advancing beyond this step
incorporated both education about this risk assessment tool and reinforcement of its use to
ensure that changes remain long standing. Consequently, the DNP student will consider
completing the inquiry process required for adopting this tool as a health care system-wide EMR
“best practice alert,” which serves as a reminder to health care providers to perform and/or
review a specific task. Step seven involved informing the staff about the progress and results of
the protocol implementation. Team members were incentivized for their participation throughout
the project with a gift card drawing every two to three weeks. Using the Iowa Model for this EBP
project guided a successful change implementation and fostered a positive learning experience.
Data measures. The B-RST™ evaluates if an individual is at increased risk for having a
BRCA genetic mutation, which assists in determining which individuals are appropriate
candidate for receiving a referral for genetic counseling with possible testing (Bellcross et al.,
2019; Cintolo-Gonzalez et al., 2017). Developed in 2007 by Dr. Cecelia Bellcross, its original
form was a paper questionnaire, named the Referral Screening Tool or RST. The current
version of this tool, B-RST™ Version 3.1, is internet-accessible and available to health care
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providers and the public (Bellcross et al., 2019). Emory University owns the rights to this tool
(A. Kerber, personal communication, July, 12, 2018). This tool has been recommended by the
USPSTF since 2013 and is credited for its ease of use (Bellcross et al., 2019; Cintolo-Gonzalez
et al., 2017; Nelson et al., 2019). The B-RST™ has been utilized in a variety of studies and
supported in many professional articles (Brannon Trexler et al., 2014; Paris et al., 2016; Pruthi,
Heisey, & Bevers, 2015; Solomon et al., 2016; Stewart et al., 2016; Wernke, Bellcross, Gabram,
Ali, & Stanislaw, 2019).
The B-RST™ is recognized for its straightforward use along with being highly validated
(Cintolo-Gonzalez et al., 2017). In 2010, the tool was advanced to the initial web-based BRST™ Version 2.0, with a sensitivity of 89.4% and a specificity of 91.5% overall with validation
against the Family History Assessment Tool, Myriad II, and a cancer family pedigree including
four generations; and when compared to the BRCAPRO and BOADICEA risk prediction models,
the sensitivity increased to 100% (Bellcross et al., 2019). Through a retrospective chart review
(N = 277), validation of B-RST™ Version 3.0 against B-RST™ Version 2.0 was reported to have
an increased sensitivity respectively (94.0% vs. 71.1%, CI 95%, p < 0.0001), but a decreased
specificity respectively (29.4% vs. 53.1%, CI 95%, p < 0.0001); the authors reported despite the
reduction in specificity, those with positive risk results were verified to be candidates for genetic
services referrals (Bellcross et al., 2019). A two-sided McNemar’s Chi-square test was used for
comparison of sensitivity and specificity of these versions (Bellcross et al., 2019).
Bellcross et al. (2019) differentiated between the following categories of B-RST™ risk
results: (1) Negative-average, (2) negative-moderate, and (3) positive. Negative-average risk
results reveal the possibility of that individual having a BRCA gene mutation is highly
improbable and the risk for breast cancer is that of the average population. Negative-moderate
risk results demonstrate the possibility of that individual having a BRCA gene mutation is low,
but risk for breast and/or ovarian cancer is elevated. Positive risk results signify the possibility
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of that individual having a BRCA gene mutation is increased by at least 5-10%, with subsequent
increased risks for breast, ovarian, and other BRCA-related cancers.
B-RST™ results were reviewed by the health care provider during the appointment. The
women who had negative-average risk results who were 40 years or older had a mammogram
ordered if due for this test and per the health care provider’s recommendations. Those whose
results were negative-moderate risk have an increased risk for breast cancer, but are not likely
at risk for a hereditary BRCA gene mutation. In addition to having a mammogram ordered for
those with negative-moderate risk results for those who were 40 years or older and due for this
test, they were also candidates for a referral to the health care system’s High Risk Breast Clinic.
The women who had positive risk results were determined to be at an increased risk for a BRCA
gene mutation. Management recommendations included a mammogram ordered for those 40
years or older and due for this test, in conjunction with offering referrals to both the High Risk
Breast Clinic and for genetic services with the health care system’s local geneticist.
Collection. Data collection for analysis included completing the B-RST™, recording
these results in the EMR flowsheet, and ordering consultation referrals. The first two steps were
completed by the MA and the last step was the responsibility of the health care provider. The
Epic information technologist initially assisted the DNP student with the process of creating
parameters and then running reports once weekly to obtain relevant data. Each provider’s daily
schedule was reviewed to verify eligible patients, referrals ordered, and evaluate
documentation. Chart audits occurred at appropriate intervals to verify if a participant had
scheduled, cancelled, rescheduled, or attended a consultation at the HRBC and/or for genetic
counseling. This data was then entered in the Excel EBP project data spreadsheet.
Management and analysis. Health care provider protocol adherence and post-referral
genetics and/or High Risk Breast Clinic consultation participation rates were evaluated.
Protocol adherence was determined if there was documentation of the B-RST™ results in the
flowsheet section of the EMR and subsequent referrals provided to those with negative-
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moderate or positive-high risk results. High Risk Breast Clinic and genetics consultations had to
be completed by March 1, 2020 to be included in the analysis of this EBP project.
Descriptive statistics were utilized to specify participant demographics. The Chi-square
test for independence was used to determine if the pre- and post-implementation groups were
independent of each other. Factorial ANOVA analyses were performed to determine if use of
the B-RST™ affected the health care providers ordering HRBC and/or genetics referrals in
comparison to the referral ordering practices for the pre-implementation group.
Comparison
One year prior to the protocol implementation, from September 24, 2018 through
December 14, 2018, eight women were provided referrals by the nine health care providers in
this practice to the local geneticist for counseling regarding their cancer family history. During
this same time frame, six women were referred to the High Risk Breast Clinic for management
of their increased risk for breast cancer. Use of the B-RST™ assisted in identification of
additional women at-risk for hereditary breast cancer who were then able to pursue additional
medical management options appropriate for this risk. Based on the use of this risk evaluation
tool, there was an increase in both referrals for genetic services and to the High Risk Breast
Clinic.
Outcomes
The primary outcomes of interest were the number of participants with negativemoderate or positive-high risk results and subsequently the amount of HRBC and genetics
referrals provided to these individuals. Consistent with the appraised literature supporting this
best practice protocol, it was anticipated that compared to simply reviewing family history in the
EMR, use of the B-RST™ would increase health care provider identification and referral of
women at-risk for hereditary breast cancer. Secondary outcomes included data regarding the
participant rates for HRBC and/or genetics consultation performance. In addition, the health
care provider protocol participation in regards to referrals ordered. Although it was suspected
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differences would be noted between adherence rates for the APRNs and physicians within this
group, participation will be ascertained for the entire Ob/Gyn practice as an aggregate.
Time
Approximately two months prior to implementing the protocol, each of the health care
providers at the Ob/Gyn office and the geneticist were recruited. Next, the DNP student trained
the medical assistants individually how to use the B-RST™. Protocol details were reviewed,
including who qualified for use of the tool and how to document these results. The EBP project
was implemented for twelve weeks, starting September 23, 2019 and ending on December 13,
2019. Genetic and/or High Risk Breast Clinic consultation participation was verified by March 1,
2020.
Protection of Human Subjects
It is imperative during the pursuit of advancing health care knowledge that the rights of
individuals are protected. Key ethical aspects prioritized during the development and
implementation of this EBP project were autonomy, beneficence/nonmaleficence, and justice.
An objective throughout this project was to provide consistent and comprehensive care to
women in adherence with the identified best practice standards. Patients were assessed using
the B-RST™ as long as the inclusion factors were met. In meeting ethical course requirements
prior to the study’s initiation, the NIH ethics web-based course entitled “Protecting Human
Research Participants” was completed on April 5, 2018 (Certificate Number 2628916). This
EBP project was found to be classified within the exempt non-research category and therefore
did not require further review from the Institutional Review Board (IRB) at Valparaiso University.
The EBP project was then reviewed and approved by the IRB at the health care system at
which it was performed (see Appendix I).
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CHAPTER 4
FINDINGS
The purpose of this EBP project was to determine if utilization of the B-RST™ risk
assessment at a nine provider Ob/Gyn practice in a Midwestern state was an effective process
for identifying women at-risk for hereditary breast cancer for the purpose of providing High Risk
Breast Clinic (HRBC) and/or genetic counseling referrals. Pre-implementation (before protocol
intervention) and post-implementation (after protocol intervention) data were compared in this
project. The pre-implementation group was comprised from a chart audit and included 880
patients who were seen one year prior. Data were collected from electronic medical records by
process of entering B-RST™ results in the EMR, reviewing populated EMR reports, and
performing chart audits for the post-implementation group. A total of 994 women had the BRST™ assessment completed during routine gynecological and new patient appointments
during this 12-week EBP project.
Participants
Pre-implementation Demographics
Demographics information was collected through an EMR chart review between the
dates of September 24, 2018 through December 14, 2018, with this range being the same 12week time frame that the EBP project was implemented in 2019. Demographic information for
this population included: age, appointment type, insurance coverage, race, and religious
preference. The EMR chart audit report that populated was unable to distinguish between
appointments or encounter types. Encounter types included patient-focused activities such as:
clinical updates, email messages, registration for tests (labs, mammogram, etc.), or
incoming/outgoing telephone calls. From the 4,181 appointments/encounters during this time
frame, every third patient chart was audited to determine if the inclusion criteria were met
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consisting of being ≥ 18 years old and seen for either an annual gynecological or new patient
appointment, which subsequently resulted in a total of 880 patients.
The mean age of the patients in the pre-implementation group was 44.89 (SD = 14.361),
with the ages varying from 18 to 83 years old. On average, these patients were ≥ 40 years old
(n = 607, 61.1%) and presented for routine gynecological examinations (n = 659, 74.9%). In
this group, the majority had commercial insurance (n = 669, 76.0%), were Caucasian or white (n
= 747, 84.9%), and Christian (n = 458, 52.0%).
Post-implementation Demographics
Information regarding demographics was obtained by running weekly EMR reports and
was determined to be consistent with those in the pre-implementation group. The ages of the
post-implementation group participants ranged from 18 to 91, with a mean age of 44.87 and a
SD = 14.337. Most participants (n = 748, 75.3%) were over the age of 18 and were seen for
routine gynecological examinations (n = 748, 75.3%). Overall, they predominantly had
commercial insurance (n = 795, 80.0%), were Caucasian or white (n = 861, 86.6%), and listed
their religious preference as Christian (n = 517, 52.0%). See Table 4.1 for additional
demographic data delineation and comparisons between the pre- and post-implementation
groups.
Changes in Outcomes
Nearly seventy-five percent (n = 745, 74.9%) of the participants had negative-average
risk B-RST™ results. The remaining quarter of the group had negative-moderate (n = 75, 7.5%)
and positive-high (n = 174, 17.5%) risk results (see Figure 4.1). This data is consistent with the
evidence from the literature. In a study performed by Wernke et al. (2019), 72.2% of the
participants had negative-average results, 9.5% had negative-moderate, and 18.3% were
positive. Per the protocol, 249 participants were eligible for a HRBC consultation and 174 for
genetics. Data for pre-and post-implementation HRBC and genetics referrals are to follow.
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Pre-implementation HRBC and Genetics Referrals
The nine health care providers at this EBP project site consisted of three each of CNMs,
NPs, and physicians. Two of the three physicians had a NP that shares patients from their
schedule. The 994 participants screened with the B-RST™ saw the providers as follows: CNM
(n = 210, 21.1%), NP (n = 244, 24.5%), physician (n = 347, 34.9%), and physician/NP (n = 193,
19.4%). Pre-implementation HRBC and genetics referral totals from these providers were
determined through an EMR chart audit for this same 12-week duration one year prior and
included HRBC (N = 6) and genetics (N = 8). For the HRBC referrals, five (83.3%) were from
the physicians/NPs and the remaining one (16.7%) was provided by a CNM. Two (25%) of the
genetics referrals were from the physician/NP and the remaining six (75%) were from the NP.
Two of the six HRBC consultations were performed, whereas three of the eight genetic referrals
were completed. See Table 4.2 and Figure 4.2 for comparisons of pre- and postimplementation HRBC and genetics referrals provided.
Post-implementation High Risk Breast Clinic Referrals
In comparison to the pre-implementation group, the total referrals to the HRBC
increased by 51. Amongst the 249 participants who qualified for a HRBC referral, n = 57
(22.9%) accepted this referral and n = 144 (57.8%) either declined or were not offered this
option. Of note, the majority of participants who were eligible for genetic counseling also
qualified for a consultation at the HRBC. An exception to this was individuals with a family
history of ovarian cancer, but without any family members with a history of breast cancer.
From the 57 HRBC referrals ordered, 30 (52.6%) were from the physicians/NPs, 19 (33.3%)
from the NP, six (10.5%) from the CNMs, and two (3.5%) from the physician.
Documentation was reviewed in the EMR with the health care providers having reported
that the HRBC referral was unnecessary for 31 participants (12.5%) or that the referral was
ordered when in actuality this did not occur (n = 17, 6.8%). The providers documented a
discussion with a HRBC eligible participant 62.7% (n = 156) of the time. If a patient declined the
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referral, this was documented 58.6% of the time. It was noted that 10 patients had a prior
history of completing a consultation at the HRBC. See Table 4.2 and Figure 4.2 for
comparisons of pre- and post-implementation HRBC and genetics referrals.
Post-implementation Genetics Referrals
Genetics referral totals increased by 24 with the post-implementation group. A total of
174 participants qualified for a referral for genetic counseling, in which n = 32 (18.4%) accepted
this referral and n = 124 (71.3%) declined or were not offered this option. The physicians/NPs
ordered 16 (50%) of these referrals, with nine (28.1%) from the NP, six (18.8%) from a CNM,
and one (3.1%) from the physician. Within eligible participants, the health care providers
documented that the genetics referral was unnecessary for three (1.7%) participants or that the
referral was ordered when in actuality this did not occur (n =15, 8.6%). Documentation of a
discussion with a participant eligible for a genetics consultation was present 54.6% (n = 95) of
the time. If a participant declined the referral, this was documented 40.2% (n = 70) of the time.
A total of 21 participants were noted to have a history of genetic counseling and/or testing
performance. See Table 4.2 and Figure 4.2 for comparisons of pre- and post-implementation
HRBC and genetics referrals provided.
Statistical Testing and Significance
IBM SPSS Statistics Standard Edition version 25 was utilized for variable and data entry,
in addition to statistical analysis performance. Frequencies were determined for pre- and postimplementation participant demographics, B-RST™ results, referrals provided, and referrals
completed (see Tables 4.1- 4.4 and Figures 4.1- 4.4). The Chi-square test for independence
was used to determine if the pre- and post-implementation groups were independent of each
other. A factorial ANOVA was performed to examine if there was a statistically significant
difference between HRBC and/or genetics counseling referrals being provided pre- and postimplementation in comparison amongst the health care providers at the Ob/Gyn practice.
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Chi-square testing. The Chi-square test is a nonparametric level of analysis that
utilizes nominal or ordinal data to distinguish if groups are similar or different, for the purpose of
assisting with determining whether an intervention caused a change versus differences between
a variable being the reason (Peters, Schmidt, & Fearncombe, 2015). The Chi-square test for
independence was used to distinguish if the demographic variables of age, appointment type,
insurance coverage, race, and religious preference were statistically significant, or independent,
between the pre- and post-implementation groups. Statistical significance for all analysis was
established as p < .05.
A chi-square test for independence was conducted comparing the demographic data of
the pre- and post-implementation groups. There was no statistically significant difference found
between these two groups on age (p = .946), appointment type (p = .855), insurance type (p =
.054), race (p = .662), and religious preference (p = .421). Subsequently, the patients included
in this sampling were considered to be representative of the patients seeking care in this
Ob/Gyn practice.
ANOVA testing. Verifying whether the means of groups vary is achieved through
ANOVA (analysis of variance) testing; this can occur for multiple means and assists with type 1
error minimization (Peters, Schmidt, & Fearncombe, 2015). Between-subjects factorial ANOVA
tests (hereafter referred to as ANOVA) were conducted with the independent variables of HRBC
referral provided or genetics referral provided with the dependent variables of health care
provider and pre- and post-implementation groups. Statistical significance for all analysis was
established as p < .05 and confidence intervals were 95.0%. See Table 4.4 for ANOVA results.
The ANOVA test was performed to ascertain if being provided a referral for HRBC
counseling varied with the health care providers at the EBP project site and the two groups (preand post-implementation). Statistically significant differences were found for the group means
of the health care providers (F(6, 1860) = 9.24, p < .001), the pre- and post-implementation
groups (F(1, 1860), = 22.01, p < .001), and lastly the interaction effect between the providers
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and these two groups (F(6, 1860), = 9.23, p < .001). Therefore, the null hypothesis was
rejected as these results indicated that the differences amongst the health care providers and
between being in the pre- or post-implementation group affected the ordering of HRBC referrals.
The ANOVA test was then conducted to establish whether genetics referrals being
ordered differed between the health care providers and the two groups (pre- and postimplementation). Statistically significant differences were found for the group means with the
health care providers (F(6, 1860) = 5.36, p < .001), the pre- and post-implementation group
(F(1, 1860) = 10.14, p < .001), and the interaction effect between the providers and the groups
(F(6, 1860) = 6.46, p < .001). Similar to the HRBC referrals, genetic referral provision
differences were noted between the health care providers and the pre- and post-implementation
groups.
Post hoc testing. Since the above ANOVA results were statistically significant, post
hoc testing was required to determine where the differences occurred within the health care
providers ordering HRBC and genetics referrals. With multiple types to choose from, Tukey
HSD was selected (Cronk, 2018). The Tukey post hoc test was not performed for the pre- and
post-implementation groups related to no additional variable being available for comparison.
The mean difference was significant at the p < .05 level.
Between the seven provider/groups previously delineated, 21 pairs of analyses
occurred. For the purpose of analyzing and interpreting the results from these pairs,
physician/NP was categorized as physician1/NP1 or physician2/NP2. CNM1, CNM2, and
CNM3 differentiated between the three CNMs. The remaining physician and NP were listed as
such.
Statistical significance was noted, indicating that the following eight pairs of providers
were statistically different from each other in regards to providing HRBC referrals: (1)
physician1/ NP1 and physician2/NP2, (2) physician1/NP1 and the physician, (4) physician1/NP1
and the NP, (5) physician1/NP1 and CNM1, (6) physician1/NP1 and CNM2, (7) physician1/NP1
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and CNM3, and (8) the physician and the NP. Regarding providing genetics referrals, the
following three pairs of providers were statistically different from one another: (1) Physician
1/NP1 and the physician, (2) physician1/NP1 and the NP, and physician 1/NP1 and CNM2. The
remaining pairs for both of these Tukey post hoc tests were not found to be statistically different.
Findings
Primary outcomes. The primary outcomes were the identification and referral of
women considered to be at increased risk for hereditary breast cancer through a B-RST™
assessment. During the 12-week EBP protocol implementation, 1253 women were eligible to
have the B-RST™ performed at their appointments and this successfully occurred for 994
participants. At the onset of this EBP project, the minimum goal was set at 75% protocol
adherence rate. At its completion, the protocol participation rate was 79.3%.
Whereas 75% (n = 745) of the participants had negative-average risk results, 75 (7.5%)
had negative-moderate risk results, and the remaining 174 (17.5%) were in the positive-high risk
category. As aforementioned, the majority of participants who were eligible for genetic
counseling also qualified for a consultation at the HRBC. Fifty-seven participants were provided
a referral to the HRBC from the 249 who qualified. Amongst the 174 participants who were
eligible, 32 patients (18.4%) received referrals for genetic counseling.
Secondary outcomes. Secondary outcomes included participant HRBC and/or
genetics consultation participation rates. Eight patients (14.0%) completed a HRBC
consultation by March 1, 2020, with an additional six patients (10.5%) having upcoming
appointments scheduled beyond this date (see Table 4.3 and Figure 4.3). Appointments were
scheduled at the HRBC and then either cancelled or not attended by nine participants (15.8%).
Nearly 60% (n = 34, 59.6%) of those eligible had not yet scheduled a consultation at the HRBC.
Genetic counseling appointments were completed by seven (21.9%) participants by March 1,
2020, without any further appointments scheduled (see Table 4.3 and Figure 4.4). Three
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participants (9.4%) scheduled appointments and then did not attend or cancelled. A total of n =
22 (68.8%) had not scheduled an appointment yet.
Although the total HRBC and genetics referrals varied amongst the health care
providers, this Ob/Gyn group as a whole ordered more of both of these during the postimplementation in comparison to the pre-implementation time period (See Table 4.2 and Figure
4.2). The total combined HRBC and genetics referrals provided in the pre-implementation
group were 14 and this increased to 89 in the post-implementation group. Four of the providers
did not provide HRBC referrals to the pre-implementation group, which decreased to one
provider during the post-implementation. Five of the providers did not provide preimplementation genetics referrals and two providers maintained this status post-implementation.
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Table 4.1
Pre- and Post-Implementation Demographic Comparison
____________________________________________________________________
Pre-implementation
Totals

n

%

Post-Implementation
n

%

____________________________________________________________________
Group (N)
880
994
Age (mean, SD)

45

14.361

45

14.337

Appointment Type
Routine Annual Exam
New Patient

659
221

74.9
25.1

748
246

75.3
24.7

Insurance Coverage
Commercial
Medicaid
Medicare
Uninsured

669
112
91
8

76.0
12.7
10.3
0.9

795
107
90
2

80.0
10.8
9.1
0.2

747
71
62

84.9
8.0
7.0

861
63
70

86.6
6.3
7.0

Race
Caucasian or White
Other
African American or Black

Religious Preference
Christian
458
52.0
517
52.0
No preference/none
372
42.3
431
43.4
Other
48
5.5
41
4.1
Jewish
2
0.2
5
0.5
____________________________________________________________________
Note. Other category for race included: Asian, Native American, and unspecified.
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Table 4.2
Pre- and Post-Implementation Referral Comparison
___________________________________________________________
Pre-implementation
Totals

n

Post-implementation
n

___________________________________________________________
Participants (N)

880

994

Referral Provided
High Risk Breast Clinic
Genetics

6
8

57
32

Referral Performed
High Risk Breast Clinic
Genetics

2
3

8
7

___________________________________________________________
Note. Pre-implementation participants consisted of patients seen by the
nine health care providers for annual exam and new patient appointments
during the same 12-week time frame one year prior.
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Table 4.3
Post-Implementation Referral Eligibility, Provision, and Performance
______________________________________________________________________
Referral Type
Frequency, Total

High Risk Breast Clinic
n

%

___Genetics_____
n

%

______________________________________________________________________
Eligible for Referral

249

25.1

174

17.5

Referral Provided
Yes
No
Documented, but not ordered
Documented as unnecessary

57
144
17
31

22.9
57.8
6.8
12.4

32
124
15
3

18.4
71.3
8.6
1.7

Referral Performed
Yes
8
14.0
7
21.9
No
34
59.6
22
68.8
Currently scheduled
6
10.5
0
0
Scheduled, then cancelled
9
15.8
3
9.4
______________________________________________________________________
Note. Eligibility results from the total participants (N = 994) who had the B-RST™
performed. Participants with positive-high risk results qualified for referrals to HRBC
and genetics.
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Table 4.4
Factorial ANOVA Results
_______________________________________________________
df

F value

p value

(effect, error)
_______________________________________________________
HRBC Referral
Provider
Group
Provider & Group

6, 1860
1, 1860
6, 1860

9.24
2.01
9.23

<.001
<.001
<.001

Genetics Referral
Provider
6, 1860
5.36
<.001
Group
1, 1860
10.14
<.001
Provider & Group
6, 1860
6.46
<.001
_______________________________________________________
Note. Statistical significance at p < .05
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CHAPTER 5
DISCUSSION
The primary objective of this EBP project was to answer the following PICOT question:
In women cared for in an obstetrical and gynecological practice, how does utilization of a breast
cancer genetics referral screening tool, as compared to the current standard of care of collecting
and reviewing family history in patients’ electronic medical record, allow women at increased
risk for hereditary breast cancer to be appropriately identified and referred for genetic
counseling within a twelve-week time frame? Upon completing data analysis, statistically and
clinically significant results supported the utilization of the protocol and assessment tool in this
office setting. The Iowa Model was an effective approach to guiding this change. Knowledge of
both the strengths and limitations with this EBP project can promote improvements and
sustainability of B-RST™ use as a standard practice of care. Recommendations focus on
improving adherence to utilization of the B-RST™ assessment, in addition to enhancing patient
participation in referral performance, in order to facilitate medical management in women at-risk
for hereditary breast cancer.
Explanation of Findings
During the 12 weeks that the EBP project occurred at the nine provider Ob/Gyn practice,
1253 patients were candidates for having the B-RST™ assessment completed at their routine
gynecological or new patient appointment. The B-RST™ was successfully completed for 994
(79.3%) participants, which achieved the goal of a minimum of 75% B-RST™ performance.
With 75% (n = 745) of the B-RST™ results being negative-average risk, the remaining 25% (n =
249) of participants were subsequently eligible for referrals to further assess and manage their
elevated risk for breast cancer. Per the EBP protocol, participants with negative-moderate risk
results were to be offered referrals to the HRBC and those with positive-high risk results to both
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the HRBC and genetics. This resulted in 249 participants being candidates for consultations at
the HRBC and 174 for genetic counseling.
Participants
Pre-implementation data were obtained for the same 12-week time period one year prior
to the protocol being implemented. This group consisted of 880 patients. The postimplementation group included 994 participants. Both of these groups were adequate in size.
The average ages were nearly identical at 44.89 (SD = 14.361) and 44.87 (SD = 14.337) for the
pre- and post-implementation groups respectively. For each of these groups, the patients were
predominantly Caucasian or white, Christian, had commercial insurance, and presented for a
routine gynecological examination. Although the results from this EBP project may be limited in
generalizability related to this population not being diverse, Chi-square test for independence
results were not statistically significant (p > .05), which indicated that the pre- and postimplementation groups were a representative sampling of the patients seeking care at this EBP
project site. This information assisted in the further determination that the protocol
implementation likely supported the results noted, instead of differences between the
demographic variables amongst these two groups.
High Risk Breast Clinic Referral Candidates and Referrals Provided
Following the EBP protocol, participants with negative-moderate (n = 75, 7.5%) and
positive-high (n = 174, 17.5%) risk results met the qualifications for receiving referrals to the
HRBC. An exception to this was participants who had a family history of ovarian cancer, but
without an incidence of breast cancer, which would slightly decrease the total participants
eligible for the HRBC. Related to potential inaccuracies in participants’ family medical history
and/or if this information was not documented by the health care provider, this exclusion was
not omitted from the total. From these 249 participants, HRBC referrals were provided to 57
(22.9%) and completed by 8 (14.0%) participants. In comparison, six referrals were ordered for
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the pre-implementation group, with an improvement by nearly ten-fold (n = 51) during the 12
weeks the EBP protocol was implemented.
Nine HRBC appointments were scheduled and then either not attended or cancelled. In
addition, six appointments remain scheduled, but had not yet occurred by the date established
to initiate data analysis. Of importance to note, several of the health care providers documented
that referrals were provided for an additional 17 participants, but in actuality these were not
ordered. Had this been accurately performed, the HRBC referrals would have increased by
29.8% to a total of 74. Suspected reasons these referrals may not have ordered include a
miscommunication between the health care provider and the MA or if the participant changed
her decision after the appointment with the provider had concluded. Lower than anticipated
rates of referral acceptance and completion occurred, which impacted the number of women
overall who could participate in appropriate medical management for their increased risk for
breast cancer. Potential participant-related concerns regarding performing HRBC consultations
are considered further in this chapter.
Factorial ANOVA test results for providing a HRBC referral were statistically significant
for: (1) The health care providers (F(6, 1860) = 9.24, p < .001), (2) the pre- and postimplementation groups (F(1, 1860), = 22.01, p < .001), and (3) the interaction between the
health care providers and the pre- and post-implementation groups (F(6, 1860), = 9.23, p <
.001). Statistical significance for analysis was established at p < .05. With the Chi-square
analyses indicating the two groups were dependent of each other, the ANOVA results
determined that the protocol implementation utilizing the B-RST™ assessment to guide ordering
HRBC referrals resulted in an increase in this performance. With Tukey HSD post hoc test
results, eight pairs of the health care providers were statistically different from one another in
regard to ordering HRBC referrals. Since the EBP protocol adherence and HRBC referral
provision varied per provider, this consequently affected whether an eligible participant would
receive a referral and is an additional area needing improvement.

HEREDITARY BREAST CANCER PROTOCOL

62

Genetics Referral Candidates and Referrals Provided
A total of 174 (17.5%) participants had positive-high risk B-RST™ results and were
appropriate for genetic consultation referrals, in which 32 (18.4%) were ordered, and seven
(21.9%) were completed. This is a four-fold rise in referrals for genetic counseling in contrast to
the eight provided to the pre-implementation group.
Three appointments were scheduled and then either not attended or cancelled, and
have since not been re-scheduled. An additional 15 participants were candidates for genetics
referrals, but these were not ordered despite being documented by the health care providers as
having occurred. If these had been completed, the total referrals would have increased by
46.9% to 47. Similarly to accepting and performing HRBC referrals, those for genetics were
also less than expected. Participant-related barriers for utilizing genetic services are explored
further in this chapter.
Comparable to the HRBC referral outcomes, the factorial ANOVA results for providing
genetic referrals were also statistically significant for: (1) The health care providers (F(6, 1860) =
5.36, p < .001), (2) the pre- and post-implementation group (F(1, 1860) = 10.14, p < .001), and
(3) the interaction effect between the health care providers and the groups (F(6, 1860) = 6.46, p
< .001). Utilization of the B-RST™, as demonstrated by the significant differences between the
pre- and post-implementation groups, supported the increase in genetics referrals. Tukey HSD
post hoc results revealed statistical difference between three pairs of the health care providers
for ordering genetics referrals. Likewise, further focus on the health care providers ordering
genetics referrals could potentially enhance appropriate participants being provided referrals.
Primary and Secondary Outcomes
Primary outcomes. The primary outcomes for this EBP project were the identification
and referral of women considered to be at increased risk for hereditary breast cancer through a
B-RST™ assessment. Chi-square test results for the pre- and post-implementation groups
indicated that the demographic variables of age, appointment type, insurance coverage, race,
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and religious preference were independent of each other, with p > .05. Factorial ANOVA results
were statistically significant (p < .01) for the changes in the HRBC and genetic referrals ordered
by the providers for the pre- and post-implementation groups. As evidenced by the data
analysis and supported in the literature, following the protocol and using the B-RST™ was an
effective process for recognizing and providing referrals for women at-risk for hereditary breast
cancer. In comparison to the HRBC referrals ordered for the pre-implementation group (n = 6),
51 additional referrals were provided to the post-implementation group (n = 57). Similarly,
genetics referrals increased by 24 from the pre-implementation group (n = 8) to the postimplementation group (n = 32). Patients at this Ob/Gyn practice will benefit from continued use
of this risk assessment tool to guide the referral process.
According to the EBP project’s findings, from the 259 patients that met the protocol
criteria but did not have the B-RST™ completed it is estimated that approximately 65 (25%)
would have also been appropriate for receiving HRBC and/or genetics referrals. Although the
MAs were responsible for performing and documenting the B-RST™ results in the EMR, the
health care providers also had access to this risk assessment tool and were ultimately
accountable for its performance in patients who met the protocol qualifications. Increasing BRST™ utilization and referral provision are necessary areas of improvement in order to provide
optimal health care to this high-risk group.
Secondary outcomes. Whereas the primary focus of this EBP project was to both
identify and provide referrals for women at-risk for hereditary breast cancer, it is essential that
successful performance of the HRBC and/or genetic consultations occurs for directing medical
management. HRBC and genetic consultation participation were secondary outcomes with low
appointment adherence rates noted for both of these. By March 1, 2020, a total of eight
(14.0%) HRBC consultations were performed from the 57 that were ordered and for the 32
participants who were provided genetic referrals, seven (21.9%) had been completed. It will be
advantageous for the patients at this Ob/Gyn practice to receive information about these
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consultation appointments and to also have their perceived barriers addressed. Further
information regarding patient-perceived barriers and recommendations for alleviating these will
be clarified in the Implications for the Future section of this chapter.
Comparison of EBP Project Findings to Appraised Literature
In accordance with the appraised literature, utilizing the B-RST™ for this EBP project
was found to be a time efficient approach for accurately identifying and providing referrals to
women determined to be at-risk for hereditary breast cancer (Anderson et al., 2015; Hilgart et
al., 2012; Solomon et al., 2016). The MAs and health care providers reported ease of use with
performing the B-RST™ assessment, entering results, locating the results in the flowsheet, and
reviewing these results with the participants. The uncomplicated nature of using the B-RST™
promoted continued use of this risk assessment tool.
Although not directly reported by the MAs or the other health care providers, yet noted
with several of this DNP student’s participants and likewise reported by Baer et al. (2013) and
Brannon Trexler et al. (2014), when patients inaccurately reported their cancer family history or
did not perceive sharing this information to be important and simply reported no history, the
accuracy of the B-RST™ risk appraisal results and consequently the management of these
results were hindered. Since one is not able to view both the participant’s cancer family history
simultaneously while performing the B-RST™ in this health care system’s EMR, the accuracy of
the cancer family history could not be verified during this process. However, this information
could be clarified afterwards with the B-RST™ repeated as needed to ensure accurate results
and appropriate medical management recommendations.
Although each of the health care providers in this Ob/Gyn practice agreed to participate
in the EBP project and follow the protocol implementation, the adherence rates were quite
varied. Two of the three physicians and two of the three midwives consistently did not
document whether they discussed the B-RST™ results with their patients. These same
providers also provided little to no referrals for HRBC and/or genetic counseling. According to
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Christianson et al. (2012), some of the barriers for optimal risk assessment tool performance
that presumably applied to the health care providers at the EBP project site included time
restraints along with knowledge and confidence limitations. Even though it was not particularly
time consuming to review results and recommended referrals with the participants, it may not
have been integrated into the appointment routine for specific providers. This lack of
consistency may have consequently affected confidence levels. In an attempt to improve
protocol adherence and confidence levels, the providers were contacted several times, in
person and/or by email or text message, prior to and during the 12-week EBP project to provide
education regarding: Details of the protocol, the use of the B-RST™, recommended
management of the three results, and updates regarding data totals (i.e. eligible participants,
weekly participants, test results, HRBC & genetic referrals). In addition, the providers were
requested to provide feedback, which was repeatedly positive. Despite these favorable
comments, obstacles persisted for certain providers with ordering referrals.
Depending on the location of an office setting, limited resource availability could be a
barrier to referral and/or genetic testing performance (Berliner et al., 2013; Christianson et al.,
2012). However, the participants in the EBP study had access to a HRBC with locations within
the two counties that the Ob/Gyn offices were located. Although the geneticist worked in only
one of the two counties, she had two offices for the participants to choose from. The HRBC had
limited appointment availability with a maximum of three consultation appointments per week.
Both of these factors potentially affected the number of consultations completed during this EBP
project.
As evidenced by the literature and supported by the increase in the post-implementation
referrals for both the HRBC and genetics, incorporating use of a risk assessment tool, such as
the B-RST™, resulted in a more thorough review, discussion, and management of a patient’s
family cancer history (Anderson et al., 2015; Baer et al., 2013; Berliner et al., 2013; Kaplan et
al., 2014). Although participant feedback was not requested at the time the B-RST™ tool was
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used, beneficial outcomes were reported to the health care provider during HRBC consultations.
Consistent with the literature, these benefits included satisfaction with the counseling
experience related to an increase in knowledge and reassurance about available medical
management options to decrease specific risk factors (Hilgart et al., 2012; Nelson et al., 2014;
Obeid, 2017).
Strengths and Limitations of the DNP Project
Strengths
Staff involved with the project. Several attributes of this EBP project promoted its
successful outcomes. Each of the individuals, involved in varying roles, had essential
responsibilities for building the foundation of the project. From the beginning, the health care
system’s Epic IT representative and the office manager volunteered their time, sharing
knowledge and skills for the follow EMR tasks: Adding the B-RST™ hyperlink, creating and
running reports, and performing chart audits. Aspects of these processes were tedious at times,
yet the final outcomes allowed the paper version of the B-RST™ to be averted and also reduced
the time required for data collection. In addition, each of the nine providers at the project site
were supportive and willing to participate. Their buy-in fostered a more positive response from
the MAs to participate in their roles for this project. The MAs not only appeared supportive of
the EBP project, but were competitive amongst each other, as they attempted to achieve the
highest B-RST™ accuracy rates and have their names chosen for one of the gift cards drawn
every two to three weeks.
Participants. Both the pre- and post-implementation groups were adequate in size, with
880 and 994 respectively, and Chi-square analyses indicated the demographics of both these
groups were a representative sampling of the patients seen at this Ob/Gyn office site. The DNP
student did not receive any information regarding negative feedback from the participants who
had the B-RST™ performed. For the majority (75%) of the participants, the results were
negative-average risk with the convenience of no further follow-up being necessary.
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B-RST™ utilization and data collection. As documented in the literature, the B-RST™
was simple for the MAs to use and the health care providers to interpret results. The simplicity
of performing this assessment promoted protocol adherence, with the goal of ≥ 75% compliance
achieved. The hyperlink to the B-RST™ remains in the EMR with the continued accessibility
allowing sustainability of utilizing the risk assessment tool and following the EBP protocol well
beyond the 12-week EBP project. Creating and running reports in the EMR saved time from
having to search for each participant’s demographic variables.
EBP model. The seven steps of the Iowa Model were valuable in guiding the process of
performing this EBP project from onset to completion. This EBP model was chosen related to it
repetitively being the foundation for successfully implementing changes, such as guidelines or
protocols, in a variety of health care settings (Iowa Model Collaborative et al., 2017). Choosing
the EBP topic and identifying the project focus accomplished the initial two steps. A unique
aspect of the Iowa Model were the three check points placed at stages in the process where it
was necessary to determine if it was appropriate to proceed to the next step, or if further
progress was needed to accomplish that current step. As the PICOT for this EBP project was
finalized, the first checkpoint was achieved.
The third step involved choosing team members, which included the: Epic IT
representative, office manager, nine health care providers, and the MAs. Key stakeholders
included one primary MA for each health care provider, with these individual recruited by the
DNP student based on knowledge of their clinical strengths and interest in the project’s focus.
The three NPs spontaneously assumed these roles and proved helpful in providing guidance to
the physicians and MAs regarding B-RST™ use and referral provision. Upon completing the
collection and review of the appraised evidence, the fourth step was completed. At this second
checkpoint, it was determined the evidence attained not only supported the change but was also
relevant to this Ob/Gyn practice.
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During the fifth step, the pilot process was determined to be successful after collecting
and evaluating the data for the first two weeks of the protocol implementation. Feedback from
the MAs and health care providers was requested, which was positive in nature. Tips were
provided for increasing accuracy of the B-RST™ utilization and ordering referrals as applicable,
along with encouragement for the successful launch of this project. This was one of the most
critical and gratifying steps to accomplish and upon doing so, the final checkpoint was achieved.
Establishing the EBP change as a permanent practice along with disseminating the
project findings were the final two steps. The objective from the beginning of this EBP project
was to develop a protocol that could prevail beyond the 12-week implementation. This has
been the most difficult step and task to achieve. One of the NPs has continued to have her MA
complete the B-RST™ once yearly on all patients who are 18 years of age or older. Although
12 weeks seemed adequate for developing a permanent change, several of the providers are
utilizing the B-RST™ on an as-needed basis; this is primarily if they are uncertain if a patient is
at-risk and eligible for referrals to the HRBC and/or for genetic counseling. One of the CNMs
shared that she had not remembered to use the B-RST™ since her MA had stopped routinely
performing the assessment for her patients; she added that she did know she continued to have
access to the B-RST™. It was recognized that one of the physician’s interest with using the BRST™ diminished during his last few months before retiring. Results from the EBP project were
shared with the health care providers and MAs after data analysis. Upon completion, the poster
along with pertinent portions of the presentation material will be shared with the staff at the
Ob/Gyn practice. This DNP student will continue to communicate with these providers about
the benefits of using the B-RST™, in addition to addressing concerns, with the goal of
consistent B-RST™ utilization and subsequent ordering of HRBC and genetic referrals.
The Iowa Model was a good fit for both the topic and office setting where it transpired.
Minor changes occurred throughout the process that did not require repeating any steps or
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varying from the intended course of action. The Iowa Model promoted a successful EBP project
experience for all involved in this protocol implementation.
Limitations
Staff involved with the project. While challenges with performing the EBP project
were certainly expected, some barriers and confounding factors encountered were not
anticipated. Although each of the health care providers agreed to participate, the level of
cooperation varied. It is surmised that some of the providers may have been agreeable to
participate due to wanting to satisfy the request, or not wanting to disappoint, one of their
colleagues. Over time, this could have consequently led to an increased probability for
diminished interest and involvement in the EBP project and protocol participation. Despite
multiple attempts being made, the efforts of the DNP student providing different forms of
communication with the objective to motivate and support continued and/or improved
adherence, may not have been adequate when faced with the busy professional schedules
confronted by the individual providers. Likewise, it was a challenging role to balance not being
overly assertive yet still adequately disseminating the areas of improvements necessary for
correctly following the protocol.
Several staff changes occurred with the MAs at this Ob/Gyn practice during the 12
weeks that the EBP project took place. During the immediate time frame leading up to and
during the EBP project there were new MAs hired and resource staffing was utilized. Although
the new and resource MAs were educated about the protocol and their roles in the EBP project,
the levels of commitment seemed less than that of the established staff. Accordingly, if the MA
did not perform the B-RST™, it was uncommon that the provider would do so him or herself;
this in turn affected the amount of patients (n = 259) who were eligible but did not have the BRST™ assessment performed. Despite multiple reminders, the patients whom the MAs
repetitively missed performing the B-RST™ assessment the most were new patients, and
particularly those presenting to initiate OB care. In hindsight, it may have been best to have the
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EBP project focus on only one group of patients, such as routine gynecological examinations, to
allow less confusion regarding who was and was not eligible. In addition, participation was
reduced from approximately the eight-week time period to the conclusion of the project. Factors
may have included the holidays celebrated (Thanksgiving and “Black Friday”) and upcoming
(Christmas), MAs and health care providers taking vacation days prior to the end of the year, or
diminishing interest as the project continued.
Participants. The participants from this Ob/Gyn setting were an average age of 45
years old, Caucasian or white, Christian, and had commercial insurance. These demographics
may limit the generalizability of the findings to other populations of interest. Total rates for
HRBC and genetics referrals provided and performed were low as many participants either
declined or accepted and then did not schedule a consultation.
B-RST™ utilization and data collection. Despite the straightforward use of performing
and entering the B-RST™ results in the EMR, the MAs would intermittently skip this task, which
affected the protocol adherence rate. Reminders were provided in person or by email if trends
were noted. A time-consuming aspect for data collection was developing the template for
running the weekly chart reports. After multiple attempts to include the appointment type in the
data by the Epic IT representative, this DNP student, and the office manager, it was ascertained
that this information would have to be verified through a chart audit of the daily schedule. In
addition, for the two NPs who saw patients from their collaborative physician’s schedule, it was
difficult at times to accurately ascertain which provider to assign the participant to. In many
cases, both the NP and the physician documented in the participant appointment notes.
Therefore, in an effort to not alter the accuracy of the data, the participants seen collectively by
the NPs and physicians were grouped together for data collection and analysis.
Implications for the Future
Several recommended areas for health care priorities and/or future research were
proposed in the appraised evidence. A common objective was establishing the most
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advantageous methods for identifying candidates appropriate for medical management along
with effective approaches for delivering genetic services (Hilgart et al., 2012; Nelson et al.,
2014; Obeid, 2017). Nelson et al. (2014) also encouraged educating at-risk individuals about
resources available to assist with improvements in overall knowledge and testing performance.
Some of the authors suggested performing a revision of their studies in order to expand
upon their previous results. This included incorporating a hereditary breast cancer risk
evaluation tool into the EMR for more convenient and comprehensive use, such as the method
used for this EBP project (Kaplan et al., 2014). To assist with substantiating their prior crosssectional study results, Solomon et al. (2016) proposed replicating their study in which the Claus
model would be used in a larger and more diversified sample population. Hilgart et al. (2012)
and Baer et al. (2013) emphasized additional studies should concentrate on the psychological
effects and long-term consequences of testing positive for a cancer gene mutation.
Brannon Trexler et al. (2014) proposed investigating methods for collaborating with an
individual’s family members who were affected by cancer and therefore more appropriate for
genetic consultations and testing. Anderson et al. (2015) considered the following health care
provider-focused study topics for the most advantageous methods to analyze: (1) Determining
best practice knowledge related to breast cancer risk appraisal; (2) improving confidence with
having conversations with patients about their risk for breast cancer; and (3) enhancing overall
quality of exchanging information with patients.
Conducting EBP projects or studies concentrated on any of the aforementioned
recommendations could strengthen the ability for health care providers to determine the optimal
methods for identifying women at-risk for hereditary breast. Consequently, these methods
should also include improving the utilization of genetics services. In regards to the health care
providers and participants who participated in the EBP project, the most applicable future
recommendations include: (1) Maintaining current knowledge about hereditary breast cancer,
associated risks, and use of screening tools (such as the B-RST™) to accurately and promptly
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identify these individuals, (2) enhancing confidence with reviewing risk assessment results and
risk factors, and (3) improving discussions with at-risk patients about management options, such
as referrals to the HRBC and/or genetics, including expectations from these consultations. At
the EBP project site, one or more of the health care providers could present up-to-date
information on these topics to their colleagues. Dialogues could be shared with tips for
discussing risk assessment results, medical resources, patient perceived barriers, and common
questions. As more patients are determined to be at-risk and subsequent conversations occur,
it is expected the providers will gain confidence in methods to best deliver this information to
their patient population.
Addressing barriers to completing genetic counseling. Low participation rates for
genetic counseling were noted with this EBP project and commonly reported in the literature. In
a study performed by Wernke et al. (2019), from the 35 women who had negative-moderate or
positive B-RST™ results, 24 were interested in attending a complimentary genetics
appointment, 20 scheduled an appointment, and only four completed genetic counseling. The
genetics consultation participation rate from the EBP project (21.9%) was comparable to the
results from this study (20%) (Wernke et al., 2019). Correspondingly, a 16% genetics referral
completion rate was noted with a study performed by Hoskins et al. (2018). These authors
reported that the leading challenges expressed by their participants regarding completing a
genetic consultation included not perceiving the appointment as being a priority and the time
commitment. For the study by Wernke et al. (2019), offering genetic counseling free of charge
removed the potential barrier of concern regarding cost. However, studies have shown that
financial concerns have been linked with underutilization of genetic services (Hayden, Mange,
Duquette, Petrucelli, & Raymond, 2017; Kne et al., 2017). Additional patient reported barriers
hindering genetic consultation completion consisted of: (a) lack of perceived benefits, (b)
inaccurate cancer risk perception, (c) insufficient knowledge and/or confidence about the
process of genetic counseling, (d) apprehension regarding privacy, (e) fear of positive genetic
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results and potential impact thereof, (f) concerns regarding the opinions and potential lack of
support family members, (g) disinterest in changing medical management despite test results,
and (h) referral location too far away (Houfek, Soltis-Vaughan, Atwood, Reiser, & Schaefer,
2015; Kne et al., 2017; Wernke et al., 2019). Health care providers should inquire about
reasons that a patient may be hesitant and/or declines a referral; accordingly, this knowledge
can promote a discussion addressing reported barriers and providing information to help the
individual with this important decision-making process (Kne et al., 2017).
Since a patient’s decision whether to pursue genetic services can be multi-faceted, in
addition to addressing barriers, the health care provider should also focus on the benefits of
genetic counseling. McAllister and Dearing (2015) performed a literature review and concluded
that patient empowerment was the primary benefit reported by individuals who completed
genetic counseling. Further benefits comprised: (a) the ability to reduce or eliminate specific
cancer risks, (b) a gain in knowledge regarding specific cancer genetic disorders, (c) the
potential positive effects the knowledge about test results has on family members, and (d) the
ability to establish long-term medical plans (Houfek et al., 2015). Although it is more practical
for the patient to make a decision during their appointment, providing a handout that focuses on
the benefits of genetic counseling and addresses common barriers may not only enhance the
patient’s knowledge and assist with decision-making, but also allow this process to be more
efficient for the health care provider.
Practice
The findings of this EBP project supported the routine use of the B-RST™ assessment
as a best practice recommendation. At the EBP project site, it was demonstrated that utilizing
the B-RST™ was a simple process for the MA, health care provider, and the patient. With the
majority (75%) of the results being negative-average risk, it was less common that additional
time was needed to review these results and further recommendations. However, it remains a
valuable use of time educating patients about pertinent risks along with options to pursue for
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decreasing these accordingly. With the B-RST™ remaining in the EMR flowsheet section of a
patient’s chart, this risk assessment tool remains available to the health care providers at this
Ob/Gyn practice. In addition, it is available to the other health care providers who work in office
settings for this health care system.
Theory
In order to best guide medical management of women at-risk for hereditary breast
cancer, it is important for health care providers to be knowledgeable about patient-perceived
barriers to participating in HRBC and/or genetic counseling. Correspondingly, the Health Belief
Model is based on the awareness of an individual’s perceptions towards preventive health care
activities, with communication being an important component (Jones et al., 2015). If an
individual does not identify as being at-risk for hereditary breast cancer, the likelihood that
referral acceptance will occur diminishes. In addition, referral participation is unlikely despite an
individual being aware of this risk, if personal advantages are not recognized to furthering
knowledge about approaches to eliminate or reduce risk factors. Thoroughly discussing the
process of a referral, barriers, and benefits, coupled with answering questions, can assist
individuals with more accurately understanding their risks and the positive contributions of
performing HRBC and/or genetic counseling.
Research
The findings of this EBP project were consistent with the literature indicating an
underutilization of genetic services. Future EBP projects and research should focus on
addressing and overcoming patient-reported barriers with the goal of increasing patient
participation rates. Timely follow-up is necessary for educating women at-risk for hereditary
breast cancer about medical management options that promote breast cancer prevention or
early detection (Kiely & Schwartz, 2014). It would be beneficial to determine optimal methods
for providing and reviewing information about what occurs at consultation appointments to
stimulate further discussion and promote consultation participation. This can also vary

HEREDITARY BREAST CANCER PROTOCOL

75

depending on the demographics of a patient population. Determining the best approach at this
EBP project site may necessitate the health care providers specifically inquiring if patients with
negative-moderate or positive-high risk results have questions, concerns, or reservations about
having HRBC and/or genetic counseling performed. The health care providers could then share
this information with their colleagues in an attempt to more adequately meet this health care
need for their patient population.
Education
Breast cancer is the leading new cancer diagnosis and the second highest cause of
cancer death in American women (ACS, 2019). Approximately 90% of individuals who have a
breast cancer gene mutation that can cause hereditary breast cancer are not knowledgeable
about this diagnosis (Drohan et al., 2012). Consequently, it is imperative that not only health
care providers, but MAs, nurses, and students (MAs, nursing, APRNs, Physician Assistants,
and medical), are educated and remain up to date about this significant risk factor. Health care
providers can read and discuss current studies with their colleagues. In-services and genetic
testing company sponsored activities can occur to educate multiple staff members as a group.
Case studies from patients within a practice can be discussed. Key stakeholders, such as those
depicted in the Iowa Model, can assist with arranging the preceding activities. Regardless of
the scheduled reason for a patient’s appointment, in the pursuit of preventive health care, the
health care provider should take the opportunity to perform a risk assessment, discuss the
results, provide additional education as needed, and order appropriate referrals.
Conclusion
Findings from this EBP project supported the use of the B-RST™ as an effective method
for identifying women who are at-risk for hereditary breast cancer at an Ob/Gyn office setting.
Improved MA and health care provider adherence to performing and utilizing the B-RST
assessment is necessary; this coupled with an increase in HRBC and genetics referral provision
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and performance, can effectively aid in the diagnosis and management of hereditary breast
cancer gene mutations with the overall goal of promoting optimal health outcomes.
Recommendations for the EBP project site include: (1) Continue B-RST™ assessment once
yearly for all patients and repeat if personal or family cancer history changes, (2) increase
documentation if HRBC or genetics referrals are offered, accepted, and/or declined, and (3)
provide patient-reported reason(s) for a referral being declined to aid in improving genetic
counseling participation rates. Considerations for the general field of health care are to: (1)
Promote health care provider awareness about genetic risk assessment tool use (such as the BRST™) and (2) enhance recognition of barriers to providing, accepting, and performing referrals
to properly address these concerns with the goal of increased referral participation. The more
the B-RST™ assessment is performed, the more lives that can be positively affected.
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Evidence Data Table

Citation

Anderson et al.
(2015)
Journal of
Oncology
Practice
Breast cancer
risk assessment
among lowincome women
of color in
primary care: A
pilot study

Population, Setting(s)

Intervention(s),
Comparison(s)

 Low income African
 Exploratory Pilot Study
American and
Hispanic women ages  Study population: N = 237
25 to 69 years old,
without a personal
 Prior to examination with
history of breast
health care provider, the
cancer, presenting for
following was collected:
annual examinations
(a) risk factor information,
at two federally
(b) baseline survey, and
assisted medical
for those consenting,
institutions in the
(c) breast cancer risk
Midwest
evaluation using the BC
Risk Screening (BRS)
web-based tool, which
simultaneously calculates
the following models: (1)
Claus, (2) modified Gail,
and (3) pedigree
assessment tool

Outcomes, Effect
Measures
 Outcome:
Determining what factors affect
women’s decisions to either accept or
decline breast cancer risk evaluation
performance
 The majority of this population
(n = 207, 87.3%) chose to be
informed of their breast cancer risk
assessment results with an increased
likelihood with women ages 40 to 49
years old with OR 5.4 (95% CI, 1.09 26.67) and 50 to 69 years old with OR
7.99 (95% CI, 1.47 - 43.44)
 Women choosing not to participate in
risk assessment result discussions (n
= 30, 12.7%) shared the following
characteristics:
(1) younger age (< 40 years old),
(2) lack of concern regarding personal
risk for breast cancer,
(3) prior history of mammogram, and
(4) lacking private insurance coverage
 High rate of BRS tool use in this
population accomplished the
following: (a) compliance with 2013
USPSTF breast cancer risk appraisal

Level of
Evidence,
Grade
Level III, B
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recommendations, and (b) in office
utilization of a tool that efficiently
performs the appraisal with
consideration of health care provider
barriers of time restraints and/or lack
of breast cancer risk knowledge
 Primary outcome:
New documentation of cancer family
history in the EMR within 1 month of
visit

 New or established
 Controlled Trial without
female and male
Randomization
patients between 18
Journal of
to 75 years old,
 Study population:
General Internal
without a family
intervention group from
Medicine
history of cancer
three practices (n = 996),
 Secondary outcome:
documented in their
control group from two
New cancer screening test notices for
Use of a webEMR, presenting for
practices (n = 637)
those with an increased risk for breast
based risk
annual examinations
or colon cancer provided by health
appraisal tool for
within five urban
care providers within 1 month of visit
 Intervention group: Use of
assessing family
academic primary
the Your Health Snapshot
history and
care medical practices (YHS) web-based risk
 Individuals in the intervention group
lifestyle factors
assessment tool linked to
were more likely to have cancer family
in primary care
the EMR prior to
history addressed with EMR
appointment with health
documentation than in the control
care provider; family health group (10.6% vs. 0.8%) with adjusted
history used to evaluate
OR 15.9 (95% CI; [3.5, 72.1], p =
risks for cancer (breast,
0.003)
colon, lung, and prostate),
with cancer screening test  No significant differences between the
alerts created in the EMR
groups for receiving cancer screening
for the health care provider
test notices, with 8 provided to the
intervention group and 0 to the control
 Follow-up phone call to
group, low results were believed due
both groups
to an EMR accessibility issue
Baer et al.
(2013)

 EMR review one month
after visit

 Use of this concise web-based risk
assessment tool raised the rate of
cancer family history charting in EMR

Level II, B
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Berliner et al.
(2013)

 Provided by the
National Society of
Genetic Counselors
(NSGC)

 Clinical Practice
Guidelines

 Recommendations
focused on three
 Revised evidencecategories:
based practice
(1) Process for collecting
NSGC practice
guideline from 2007
and evaluating personal
guideline: Risk
recommendations for
and family histories, in
assessment and
health care providers
order to assess women’s
genetic
caring for women who
cancer risks, and provide
counseling for
either have or are at
appropriate referrals for
hereditary breast increased risk for
genetic services
and ovarian
breast and/or ovarian
cancer
cancers
(2) Cancer risk appraisal
model use including:
(a) BOADICEA,
(b) BRCAPRO, (c) Claus,
(d) Gail, and (e) TyrerCuzick/IBIS
Journal of
Genetic
Counseling

(3) Opportunities for
medical management
comprising: (a) screening
tests and examination
maintenance,
(b) medications, and
(c) surgical options
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 Best practice recommendations:
(1) Consult guidelines to determine if
a woman is a candidate for cancer
genetic testing and provide
individualized health care riskreducing strategies
(2) Consider BRCA and other
applicable gene mutations
(3) Perform a cancer risk evaluation
utilizing models to determine
subsequent approach for health care
management
(4) Determine medical management
options based on medical expertise,
cancer family history, assessed risk,
and outcome of genetic testing
(5) Arrange referral to a genetics
professional to provide resources to
support educational and emotional
needs
(6) Explain current, multi-faceted
consequences of genetic testing

Level IV, B
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Brannon Trexler
et al.
(2014)
Annals of
Surgical
Oncology
Implementing a
screening tool
for identifying
patients at risk
for hereditary
breast and
ovarian cancer:
A statewide
initiative

 Primarily minority
(73.2% African
American and 8.0%
Hispanic) and lowincome women ages
14 to 85 years old
without a personal
history of cancer
obtaining health care
at one of six
participating public
health departments in
a southern U.S. state

 Demonstration Project
 Study population:
N = 2159
 Use of the breast cancer
genetics referral screening
tool (B-RST™), while
attaining the medical
history prior to health care
provider examination, to
identify and manage
appropriate at-risk women
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 Outcomes:
(1) Integrating the B-RST™ within this
selected minority population to
recognize women with increased
HBOC risk
(2) Assisting with the health care
management of those having positive
B-RST™ results
(3) Educating staff about cancer
genetic topics with the goal of
accurate utilization of the B-RST™

 Of the participants:
 Staff educated on
(a) 130 (6.0%) had positive B-RST™
hereditary breast and
results,
and
ovarian cancer (HBOC)
(b)
110
(84.6%)
then consented to be
syndrome and how to use
contacted,
with
the B-RST™ through the
(c) 67 (60.9%) then provided
following: (a) personal
clarification of family history
stories of women with a
(d) 47 (42.7%) of these women were
BRCA gene mutation,
successfully
contacted and
(b) surgeon presentations,
determined
to
be appropriate for
(c) observation and use of
testing
per
current
medical society
the B-RST™
guidelines, and
(e) 14 (12.7%) performed cancer
genetic testing, with
(f) 1 (7.1%) woman being diagnosed
with a BRCA2 gene mutation
 Use of the B-RST™ promoted
identification of woman at-risk for
hereditary HBOC; knowledge
increased in staff as demonstrated by
improved post-activity test results

Level III, A
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 Health care providers  Qualitative Study
with a variety of
specialties and an
 Study population: N = 16,
average of 23 years of
with 14 physicians and 2
Journal of
experience from a
mid-level providers from 9
Genetic
community-based
medical practices
Counseling
medical system on the
East Coast
 Three focus meetings with
The use of a
discussion of nine
family history
questions related to
risk assessment
current practice and future
tool within a
use of the MeTree risk
community
assessment tool at a local
healthcare
oncology center, with
system: Views of
subsequent shared
primary care
obligation of these results
providers
with a patient’s primary
care health care provider
Christianson et
al.
(2012)

 MeTree is a web-based
tool for evaluation of
inherited risks for breast
and colon cancers, in
addition to thrombophilia
disorders

Hilgart et al.
(2012)
Cochrane
Database of

 Females and males
 Systematic Review
across the lifespan (a)
(of RCTs)
at risk for breast
cancer due to family
 Performed to update 2007
history, (b) without a
systematic review
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 Outcome:
Determine health care provider
perceived challenges with integration
of a risk appraisal tool to resolve
these factors and improve its future
utilization

Level III,
A/B

 Data coded and analyzed with themes
categorized into the following:
(1) current methods for evaluating risk
of medical conditions
(2) barriers associated with obtaining
and using family health histories
(3) challenges associated with
applying family history to
individualized health care strategies
(4) obstacles with performance of the
MeTree tool at the oncology center
(5) medical and educational needs
 Consideration and alleviation of
anticipated health care provider and
patient challenges, with the availability
of necessary resources, are essential
components to consider prior to
implementation of a risk assessment
tool
 Outcomes for those at increased risk
for familial breast cancer with
assessment of:
(1) Methods for performing risk
evaluation

Level I, A
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Systematic
Reviews

personal history of
breast cancer, and (c)  Total of 8 RCTs, with 5 (N
(2) Approaches for providing genetic
with or without a
health care
= 1973) new to this update
Cancer genetic
known BRCA gene
risk assessment
mutation
(3) Differences between risk
 Study interventions
for individuals at
evaluation performed by a genetic
comprised:
risk for familial
specialist or a non-genetic specialist
 Individual vs. group
breast cancer
genetic counseling
(Review)
 Studies revealed genetic services
(include # of studies
provide: (a) a decrease in cancer
focused on each topic)
anxiety and enhanced emotional well(2)
being; (b) increased personal risk
 Surgical consultation
perception accuracy and knowledge
with or without hereditary
concerning breast cancer and genetic
risk assessment (1)
services, and (c) overall satisfaction
 Web-based risk
with use of genetic services
assessment tool used in
a clinic (1)
 Community vs. regional  With the benefits of genetic services
considered to outweigh the harms,
genetic services (1)
recommendation that a hereditary
 Phone vs. in-person
breast cancer risk assessment is
counseling (1)
performed to determine if a referral for
 Counseling performance
genetic consultation is appropriate
vs. delayed counseling
(3)
 Provision of a letter vs.
in-person consultation
(1)
 Appraisal of
psychological effects of
cancer risk evaluation (8)
Kaplan et al.
 Women ages 40 to 74  Randomized Controlled
 Outcomes:
(2014)
years old without a
Trial
(1) Frequency of patient-provider
previous history of
breast cancer risk and risk reduction
Cancer
breast cancer
conversations
 Study population:
Epidemiology,
receiving health care
(2) Genetic services referrals
intervention (n = 580) and
Biomarkers &
at two U.S.
(3) EMR reporting of these activities
control (n = 655);

Level I, B
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Prevention
A randomized,
controlled trial to
increase
discussion of
breast cancer in
primary care

metropolitan primary
care medical offices

randomized after baseline
phone interviews using
statistician-developed
sequence codes
 Intervention of breast
cancer risk assessment
using an office-based webbased tool, BreastCARE,
to stratify breast cancer
risk using the follow for risk
appraisals: (a) Referral
Screening Tool, (b) Gail
Model, and (c) Breast
Cancer Surveillance
Consortium risk model
 Interventions:
(a) Baseline phone
interviews and risk
assessment, (b)
BreastCARE tablet use, (c)
one to two week post-visit
phone survey, (d) six
month post-visit EMR
review

Nelson et al.
(2014)

 Population of interest:  Systematic Review
Women across the
(of multiple study types)
lifespan provided
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 BreastCARE use increased frequency
of patient-provider discussions
regarding:
(a) cancer family history, OR 2.07,
95% CI [1.34, 3.20]
(b) breast cancer risk, OR 4.78, 95%
CI [2.90, 7.89]
(c) genetic services, OR 5.99, 95% CI
[2.69, 13.3]
(d) high-risk clinic referral, OR 5.32,
95% CI [2.21, 12.8]
 BreastCARE use increased
documentation in intervention vs.
control groups:
(a) cancer family history (10.2% vs.
5.5%, p = 0.006)
(b) breast cancer risk (5.3% vs. 0.2%,
p < 0.001)
(c) genetic services (3.3% vs. 0.9%, p
= 0.005)
 Especially for women at risk for
hereditary breast cancer, use of a
web-based risk appraisal tool
increases risk and medical
management options conversations
 Outcomes of benefits and harms
assessed in three areas:
(1) BRCA risk evaluation tool use

Level III, A

HEREDITARY BREAST CANCER PROTOCOL

97

health care in
(2) Genetic services results
 Performed to update 2005
locations similar to the
(3) BRCA management options for
USPSTF
U.S. without a
malignancy and mortality reduction
recommendations
personal history of a
Risk
BRCA gene mutation  Total of 27 studies, with 16  Comparison of sensitivity between
assessment,
or BRCA-related
risk models/tools, with the Referral
new for this update
genetic
cancer(s)
Screening Tool having a high
(including RCTs,
counseling, and
sensitivity (>89%)
systematic reviews, cohort,
genetic testing
 Models/tools used in
and case-control studies)
for BRCAthe following
 Risk perception accuracy generally
related cancer in
countries: Brazil,
increased and worry decreased after
 Variety of interventions
women: A
Canada, United
genetic counseling
measuring: (a) five risk
systematic
Kingdom, and the
models/tools; (b) risk
review to update
U.S.
perception and cancer
 Best practice recommendation:
the U.S.
worry; and (c) tests, meds,
Weigh individualized benefits, harms,
Preventive
and surgeries to decrease
and risks when assessing risk,
Services Task
risk of BRCA-related
referring for genetic services, or
Force
cancers
offering medical management to
recommendation
decrease cancer risk; more studies
recommended
Annals of
Internal
Medicine

Obeid
(2017)
The Joanna
Briggs Institute
EBP Database
Breast cancer
(familial):
Classification
and care. JBI
Evidence
Summary

 Population of interest:  Evidence Summary
Women across the
lifespan at increased  Resources included two
risk for hereditary
Cochrane Database
breast cancer being
systematic reviews,
provided primary,
evidence from the National
secondary, and
Institute for Clinical
tertiary levels of health Excellence, and one each
care
of the following: metaanalysis, RCT, crosssectional observational
study, epidemiological
study, and literature review

 Unable to perform quantitative metaanalysis due to study heterogeneity
 Best practice recommendations for:
(1) patient-focused care; (2) cancer
family history and provider referral;
(3) screening; and, (4) genetic
services
(1) Patient-focused care: Respecting
patient’s personal decisions, providing
educational handouts, determining
and discussing risk level,
communicating effectively, involving
family members when appropriate
(grade B)

Level IV, A
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(2) Cancer family history and provider
referral: Evaluating breast cancer risk
by obtaining a history including first
and second- degree family members,
creating protocols incorporating
referral process (grade B)
(3) Screening: Recommending
mammography, considering adding
magnetic resonance imaging (MRI) as
indicated, considering gene mutations
specific to cancer family history
(grade B)

Solomon et al.
(2016)
BMC Family
Practice
Contribution of
extended family
history in
assessment of
risk for breast
and colon
cancer

 Women with an

average age of 63
years old receiving

services at a
mammography center 
in a Northeastern U.S.
city


(4) Genetic services: Assessing risk
and referring appropriate candidates
for genetic counseling with potential
testing (grade B)
Cross-Sectional Study
 Outcomes: Identification and
comparison of individuals qualifying
for cancer genetic services based on
Study population (N = 499)
either limited/first-degree or
comprehensive/first and secondQuestionnaire completion
degree family histories in order to
at time of mammography
determine appropriate candidates for
services
genetic services referrals
Recommendation of
 Applying ACS guidelines, 22% of atadditional breast medical
risk women qualifying for genetic
management options
services were missed using
based on the use of the:
limited/first-degree family history
(1) ACS and NCCN
screening guidelines,
(2) Claus model for breast  Using the Claus model, 3.6% (n = 18)
had more than a 20% lifetime breast
cancer risk estimation, and
cancer risk, with 5 of these 18 women
(3) breast cancer genetics
recognized using limited/first-degree
referral screening tool

Level III, B
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family history
 Using the RST, 1.8% (n = 9) qualified
for breast cancer genetics referral,
with 7 of these 9 women recognized
using limited/first-degree family
history
 Accurate cancer genetic risks require
obtaining and evaluating
comprehensive/first and seconddegree family histories
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Appendix D
Permission to Use B-RST™

Bellcross, Cecelia A.

Wed, Jul 10, 2019 9:17 AM

to me
Hi Chrys –
Thank you for your interest in B-RST™. You can view the most updated version at
www.brcagenescreen.org. The attached paper describes the validation.
What needs to be done on your end depends on how you/Epic are going to use it. If you are just
going to create a hyperlink using the above URL, no specific licensing is required, and you have
my permission.
If however, EPIC wants to imbed the program within the EMR, this would require a licensing
agreement as the program/algorithm is intellectual property owned by Emory. Doing the latter
can allow for direct integration of the result report into the EMR, as well as interface
customization. The licensing agreement would need to be with EPIC, and they would pay the
associated fee. This would also allow them to market it as part of their EMR package to others.
Please let me know which of the above options you are interested in. I’m happy to discuss by
phone if it is helpful.
Best,

Cecelia
Cecelia A. Bellcross, PhD, MS, CGC
Associate Professor
Director, Genetic Counseling Training Program
Emory University School of Medicine
Department of Human Genetics
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Appendix E
B-RST™ Results Patient Handout

Understanding Your Breast Cancer Genetics
Referral Screening Tool (B-RST™) Results
Negative – Average Risk




According to the information you provided today, your results indicate that you have an average
risk for breast and/or ovarian cancer to occur
Based on your personal & family cancer history, you are not likely to have inherited a BRCA gene
mutation that can significantly increase your risk for breast and/or ovarian cancer
If you are at the appropriate age, you should have screening mammography according to your
health care provider’s recommendation based on current guidelines

Negative – Moderate Risk





According to the information you provided today, your results indicate that you have a moderate,
or greater than average, risk for breast and/or ovarian cancer to occur
Based on your personal & family cancer history, you are not likely to have inherited a BRCA gene
mutation that can significantly increase your risk for breast and/or ovarian cancer
If you are at the appropriate age, you should have screening mammography according to your
health care provider’s recommendation based on current guidelines
You should consider a consultation at the High Risk Breast Clinic through St. Mary Medical
Center (locations in East Chicago, Hobart, Munster, and Valparaiso) to discuss management
options for this increased risk for breast cancer

Positive - High Risk


According to the information you provided today, your results indicate that you have a high, or
much greater than average, risk for breast and/or ovarian cancer to occur
 Based on your personal & family cancer history, there is a possibility you have inherited a gene
BRCA mutation that can significantly increase your risk for breast and/or ovarian cancer
 If you are at the appropriate age, you should have screening mammography according to your
health care provider’s recommendation based on current guidelines
 You should consider a consultation at the High Risk Breast Clinic through St. Mary Medical
Center (locations in East Chicago, Hobart, Munster, and Valparaiso) to discuss management
options for this increased risk for breast cancer
 You should also strongly consider a consultation with a geneticist to discuss your personal and
family cancer history in more detail, in order to determine if you are a candidate for cancer
genetic testing
Note: This screening tool is not a diagnostic test. Negative-average risk results do not indicate you will
not ever have breast and/or ovarian cancer occur. Likewise, negative-moderate & positive-high risk
results do not indicate you will ever have breast and/or ovarian cancer occur.
Adapted from the Result sections of the Breast Cancer Genetics Referral Screening Tool (B-RST™),
brcagenescreen.org, Copyright 2015 - 2019 Emory University, created by Cecelia Bellcross, PhD, MS, CGC
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Appendix G
B-RST™ Project Tip Sheet for Providers

B-RST™ Project Tip Sheet for Providers
Who qualifies: Women > 18 y/o presenting for an annual exam or
new patient appointments (only performed once)
Who does not qualify: Women w/dementia or developmental
delays/mental retardation

Steps:
1. Results can be reviewed in the Flowsheet tab and will be marked on the
handout entitled “Understanding Your Breast Cancer Genetics Referral
Screening Tool (B-RST™) Results”
2. 1 of 3 results will display upon completing use of the tool (negativeaverage, negative-moderate, positive-high)
3. Negative-average risk results: Order mammogram as appropriate
4. Negative-moderate risk results: Order mammogram as appropriate,
offer referral to High Risk Breast Clinic
5. Positive-high risk results: Order mammogram as appropriate, offer
referral for both the High Risk Breast Clinic and for genetic counseling
6. It is recommended to note in your charting that the B-RST™ results
were reviewed and if referral(s) were offered & then accepted or declined
7. Please inform me of any questions you or the patients have!
8. THANK YOU for participating in my project!
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Appendix H
B-RST™ Project Tip Sheet for MAs

B-RST™ Project Tip Sheet for MAs
Who qualifies: Women > 18 y/o presenting for an annual exam or
new patient appointments (only performed once)
Who does not qualify: Women w/dementia or developmental
delays/mental retardation
Steps:
1. Go to the Flowsheet tab
2. Click on B-RST™
3. Click on hyperlink
4. Answer questions with patient
5. 1 of 3 results will display upon completing use of the tool (negativeaverage, negative-moderate, positive-high)
6. Enter this result in the 2nd line of the B-RST flowsheet by clicking on the
magnifying glass & also mark this result on the patient handout,
“Understanding Your Breast Cancer Genetics Referral Screening Tool (BRST™) Results”, & place this handout back in the plastic patient folder for
the provider to review with the patient
7. Patient can refer to the exam room copy of the handout that will be on
the desk top in a plastic protector
8. Place referrals for High Risk Breast Clinic and/or genetic consultations
as ordered by the provider (common diagnoses will be family/personal
history of breast cancer, increased risk for breast cancer)
9. Please inform me of any questions you, the providers, or the patients
have!
10. THANK YOU for participating in my project!
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